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Abstract
Functional characterization of Phosphodiesterase-4A in behavior
Rolf T. Hansen III
Cognitive disorders such as depression, anxiety, and senescent-induced memory loss are
a growing pandemic in the world. Anxiety is the most common psychiatric disorder in America,
affecting upwards of 50 million people a year; depression has a lifetime prevalence of 20% of
the population, and it’s predicted pathological memory disorders such as Alzheimer’s disease
(AD) will reach exponential levels by the year 2050. While there are treatments for anxiety and
depression, far less success has been reached with therapeutics for AD. Phosphodiesterases
(PDEs) may be a potential novel target for future therapeutics aimed at combatting these
psychiatric illnesses and neurodegenerative diseases. PDEs are a “super family” of 11 smaller
enzyme families expressed throughout the body that degrade the cyclic nucleotides cAMP
and/or cGMP, essentially acting as an off switch for intracellular cAMP and/or cGMP signaling.
In particular, one member of this family termed PDE4 is highly expressed in regions of the brain
that may play a role in these psychiatric disorders such as the prefrontal cortex (PFC),
hippocampus, amygdala, and striatum. PDE4 has four subtypes (A, B, C, and D), of which only
PDE4C is not highly expressed in the brain. It has been found through the use of genetic
manipulation that PDE4D is highly involved with memory and depressive-like behavior, and
PDE4B is involved with anxiety and release of inflammatory factors from immune cells;
however, the functional role that PDE4A plays in behavior was not known. The purpose of this
dissertation was to characterize the functional role of PDE4A in behavior through the use of
PDE4A KO mice, and a battery of behavioral and biochemical tests. We found that PDE4A KO
mice displayed a strong anxiogenic profile, and a prolonged release of corticosterone in
response to a stressor. In addition, they also displayed enhanced emotional memory. PDE4A
KO had no effect on depressive-like behavior, and decreased the training latency in the Morris
Water Maze. PDE4A KO mice were also obese which was not due to hyperphagia or decreased
locomotor activity. It was found that PDE4A KO decreased the levels of the major metabolic
hormone T3. These results suggest that with further characterization, PDE4A may be a novel
target in the future for anxiety or emotional memory disorders, as well as obesity.
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Chapter 1
BACKGROUND AND OBJECTIVES
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1.1

Cognitive disorders
Cognitive disorders such as pathological anxiety, depression, and both non-pathological and
pathological memory loss are a growing pandemic in the United States and the rest of the
world. The following sections will review what defines these disorders, current treatments, and
the limitations and side effects of current treatments.

1.1.1. Pathological Anxiety. Anxiety is a physiological, psychological, and behavioral state induced in
animals and humans by a threat to well-being and survival, either actual or potential (Steimer
2011). The “potential” aspect of anxiety is what directly contrasts it from “fear”; fear is a
reaction of the body to immediate and present danger, while anxiety is a reaction of the body
to future events that may or may not occur. Due to the fact that anxiety is anticipatory, it can
be argued that anxiety is an essential behavior necessary for the survival of species, and
probably evolved as an adaptive survival mechanism for animals to avoid danger, thus
increasing the chances of mating and passing on their genes. While these behaviors may have
evolved to be beneficial, in pathological anxiety animals or humans are unable to appropriately
adjust to varying degrees of stress whether real or perceived. Particularly in humans,
pathological anxiety has manifested as the most common psychiatric disorder in the country,
affecting around 18% of Americans and costing the American economy over 50 billion dollars a
year (Greenberg et al. 1999; Kessler et al. 2010). The diagnostic and statistical manual of
mental disorders V (DSMV) is the standard diagnostic manual for mental health physicians
across the country to diagnose psychiatric disorders, and has classified anxiety into 12 separate
disorders including: separation anxiety disorder, selective mutism, specific phobias, social
2

anxiety disorder, panic disorder, panic attack (specifier), agoraphobia, generalized anxiety
disorder, substance/medication-induced anxiety disorder, anxiety disorder due to another
medical condition, other specified anxiety disorder, and unspecified anxiety disorder. This
current list of anxiety disorders excludes two additional anxiety related disorders that were
previously included in the DSM-IV-TR known as obsessive-compulsive disorder (OCD) and
posttraumatic stress disorder (PTSD); these two disorders have now been moved to different
sections in the DSM-V. From this list of 12 anxiety disorders, the most putatively common and
well known condition is generalized anxiety disorder (GAD). Generalized anxiety disorder is a
condition that develops slowly, involving both environment, life stresses, and genetics, with an
average onset around 31 years of age. In this condition, individuals are unable to appropriately
adjust to the realistic stressors of life. They are filled with anxiety, and have difficulty
extinguishing their concerns about situations in life, even though these situations might never
occur, or their anxiety is significantly more intense than the situation warrants (Baldwin et al.
2013). Normally because of this anxiety they have trouble sleeping, and can have significant
problems functioning socially or maintaining a job (Katzman 2009). Due to this constant
pathological anxiety and subsequent stress that is placed on their bodies, physical symptoms
such as hot flashes, nausea, loss of breath, headaches, muscular tension and instability, and the
frequent feeling of needing to go to the bathroom begin to manifest which can result in a
positive feedback loop, making the internal anxiety even worse. For the remainder of this
dissertation unless otherwise specified, GAD will be the main focus of anxiety-related
discussion.
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Typically in the clinic, the diagnosis of GAD requires that the individual have persistent
anxiety and worry on most days of the week for a period of 6 months or longer. In addition, at
least 3 additional criteria must be met such as restlessness, concentration problems, sleep
disruption, muscular tension, irritability, or fatigue. To provide an objective measure of an
individual’s anxiety, the Hamilton rating scale for anxiety (HAM-A) or the clinical global
impression scale (CGI) are often used (Sramek et al. 2002). With the HAM-A, the individual is
scored on 14 different items that can be ranked on a scale of 0-4. The scores are then
combined with a maximum score of 56 possible. The score of the HAM-A correlates with the
severity of anxiety, with 17 or less indicating mild anxiety, 18-24 intermediate anxiety, and 25
and up severe anxiety (Hamilton 1959). The CGI scale is an additional scale that is often used by
mental health professionals for a broad spectrum of disorders. The CGI scale is a 3 component
scale that rates the severity of a person’s disorder (anxiety in this case), their global
improvement over time, as well as the efficacy of a treatment. The severity of the person’s
disorder is ranked on a 7 point scale rated from 1 (normal) to 7 (very severe); the overall
improvement of the patient is ranked 1 (very much improved) to 7 (very much worse), and the
overall effectiveness of a drug is ranked as unchanged or worse, minimal, moderate, or marked.
For patients that aren’t assessed for certain values a “0” is assigned (Guy 1976). Perhaps the
double-edged sword component of the CGI is that it is subjective. This scale requires a clinician
with experience in the treatment of anxiety disorders to be able to compare to what is
“normal” and what they think the severity of the patient is. Due to this subjectivity, this scale is
more than just a “checklist” and perhaps brings a human element into the diagnosis of the
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disorder, however like many things this rating could differ between various clinicians (Busner
and Targum 2007).
1.1.2. Depression. Depression is a chronic psychological condition characterized by extreme sadness
for prolonged periods of time, and loss of motivation and reward also known as anhedonia.
Like anxiety, depression is a very prominent psychiatric disorder which affects about 17% of
Americans, is one of the leading causes of disability worldwide, and is the 8th leading cause of
death in the United States. The high prevalence of depression has a huge economic burden on
America, which is estimated to be around $30-44 billion dollars a year (Greenberg et al. 1999).
While the evolutionary advantage of depression is difficult to determine, like anxiety, many
believe that depression may have evolved to cause “psychic pain”, which in turn causes the
individual to try to avoid future experiences for events that caused that pain which could
possibly be a life threatening experience. However, like anxiety, this system can become
extremely dysregulated in humans, and the pathological depression which we know today is a
direct result of that dysregulation.
Some diagnostic criteria for depression include: significant changes in weight, changes in
the sleep cycle, increased agitation or catatonic states, significant fatigue or loss of energy,
recurrent suicidal thoughts, excessive feelings of worthlessness or guilt, and finally a diminished
ability to concentrate and think in parallel with indecisiveness. The severity of depression can
be scored with the CGI, and also the Hamilton rating scale for depression (HAM-D) which is the
depression counterpart to the HAM-A (Hamilton 1967). An additional test to measure
depression is known as the Beck Depression Inventory (BDI). This test requires the evaluation
of 21 different items that can be ranked 0 to 3. The total score is looked at and a score larger
5

than 10 indicates mild to moderate depression while a score over 18 indicates moderate to
severe depression (Forkmann et al. 2011).
1.1.3. Memory disorders. There are a plethora of cognitive conditions and external causes which can
manifest as memory loss, however, normal senescent-induced memory loss and pathological
aging (Alzheimer’s disease, AD) are two of the most putatively well known. Aging, also known
as senescence, can be defined according to the Dorland Medical Dictionary as “the process of
growing old, especially the condition resulting from the transitions and accumulations of the
deleterious aging processes.” The knowledge of the deleterious effects of senescence is not a
recent or novel discovery; in fact, it has been known for thousands of years that certain
biological processes become less efficient with increasing age while other processes remain
intact (Berchtold and Cotman 1998; Roman 1999).
In particular, memory decline has been one of the most noted and observed changes
correlated with increased biological age. However, different types of memory are affected to
varying degrees, and not all aged individuals are affected (Rowe et al. 1998; Perls 2006).
Among the forms of memory most commonly affected in aged individuals are working memory,
episodic memory, spatial memory, and long term memory (LTM). The other forms of memory
more commonly spared from the aging process include short term memory (STM), procedural
memory, and semantic memory (Light 1992). While STM and working memory are similar in
that they both involve memory over a limited period of time, working memory differs from STM
in that it requires the active manipulation of information being held in attention, like baking a
cake or doing arithmetic. In contrast, STM is the simple maintenance of that information over a
short period of time, such as remembering a phone number.
6

It is also important to identify the main differences between non-pathological aging and
pathological aging such as AD. Previous dogma suggested that alongside normal senescence
there was a significant decrease in the neuronal number (Brody 1955; Shefer 1973; Henderson
et al. 1980). Indeed, initial studies showed that aged brains had significantly less neurons, and
thus the conclusion was made that with aging neuronal death occurred. However, recent
studies have mostly proven this to be untrue (Peters et al. 1998). It is now generally believed
that with senescence there is no significant decline in the number of neurons, and previous
findings showing neuronal loss with aging have been discovered to be an artifact due to the
processing of aged brains (Haug 1985). Young brains actually shrink much more in the fixation
process, making them much denser (neurons per unit of area), and at first glance appearing to
grant them higher neuronal counts over aged brains (Peters et al. 1998). When this
confounding variable is accounted for and through the use of unbiased stereological methods,
it has been shown that the aged brain has no significant neuronal loss (Giannaris and Rosene
2012). While the aged brain is slightly smaller in weight and volume (Skullerud 1985), this is
most likely caused by a decrease in neuronal size and somatic density (Terry et al. 1987). An
additional theory was that alongside senescence there was a loss of synapses in the brain
(Geinisman 1999). However some studies have shown that there is actually no change of
synapses in hippocampal CA1 of aged rats, suggesting that memory deficits observed in
senescence may in fact be functional in nature (Geinisman et al. 2004). This is further
confirmed through findings that microcolumns in area 46 of the aged rhesus monkey lose
strength with age despite the fact the neuronal density and number is unchanged (Cruz et al.
2004).
7

AD is a significant diversion of the aging process, and has many differences from normal
aging. After being diagnosed with AD, there is an average survival of 5-10 years, and individuals
over the age of 85 have a 50% chance of contracting this disease (Drachman 2006; Herrup
2010; Podtelezhnikov et al. 2011). While normal aging has now been shown to have no
significant changes in the neuronal number, AD is defined by massive atrophy in the brain
which results in cognitive deficits much more severe than gradual senescent-related decline
(Scheltens et al. 1995; Jack et al. 1997; Drachman 2006; Glisky 2007; Herrup 2010;
Podtelezhnikov et al. 2011). Why and how normal aging turns into AD is currently unknown,
but it is known that other than familial-inherited AD, age is the largest risk factor for sporadic
AD; in fact, some have suggested that AD is an aberrant form of aging that rapidly accelerates
the aging process of the brain (Podtelezhnikov et al. 2011). In a fascinating study looking at
gene expression in aged and demented brains, it was found that AD brains had significant
changes in genes involved with lipid metabolism, the stress response, inflammation, and
peculiarly those involved with cell adhesion, migration, and morphogenesis, baring a striking
resemblance to patterns of gene expression also observed in epithelial mesenchymal transition
(EMT) tissues (Podtelezhnikov et al. 2011). These findings raise fascinating points and reveal
the similarity AD has in common with EMT, suggesting a major transformation in brain tissue
physiology and receptor signaling is occurring in AD. When the data obtained from the normal
aged patients was extrapolated, it was predicted that in non-pathological aging, normal
subjects would not reach AD cognitive-like levels until 140 years of age (Podtelezhnikov et al.
2011).
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Thus, in normal aging, even though mild memory loss is occurring and there is a gradual
decrease in brain weight, it seems as if there is no significant neuronal death occurring and that
most of the observed behavioral deficits may be functional in nature. This is in direct contrast
with AD, which may start out as an aberrant aging process which is functional in nature, but
then quickly progresses to anatomical changes through large scale inflammation, gliosis, and
loss of neurons. Due to the fundamental differences in these two aging processes, it is more
than likely that no one “silver-bullet” therapy exists for both conditions in all severities. The
more feasible approach may be that multiple therapies would need to be used for the different
processes, and different times in the progression and severity of AD.
The diagnosis of AD is often a difficult one, and requires health care professional to
exclude many additional factors which could be the cause of the declining mental health such
as: delirium caused by urinary tract infections, vascular dementia, Parkinson’s induced
dementia (Lewy-body disease), frontotemporal dementia, hydrocephalus, Huntington’s disease,
traumatic brain injury, vitamin deficiencies, endocrine conditions, prion diseases, liver
disorders, brain tumors, and immune disorders just to name a few. The level of cognitive
impairment is often measured through the administration of the mini-mental state examination
(MMSE). This is a 30 point questionnaire which asks a number of simple questions testing
several categories such as: orientation to time, orientation to place, registration, attention and
calculation (tests working memory as well), recall, language, repetition, and complex
commands. The various scores from these questions are summarized, and the total score out
of 30 is used to make an assessment on the level of cognitive impairment. Typically a score of
27 or higher indicates average cognition; scores less than 9 indicate sever cognitive impairment,
9

scores 10-18 indicate moderate impairment, and scores 19-24 indicate mild cognitive
impairment (Mungas 1991). Interestingly, it has also been shown that the MMSE can be used
to differentiate various dementias from one another (Jefferson et al. 2002; Ala et al. 2002;
Palmqvist et al. 2009). In addition to the MMSE, the Alzheimer’s disease Assessment ScaleCognitive (ADAS-cog) is a separate scale that can be used to monitor the severity and progress
of AD (Graham et al.)
1.2.

Current treatments for cognitive disorders and drawbacks

1.2.1 Treatments for anxiety. There are multiple modes of therapy that can be prescribed to help
combat pathological anxiety in humans such as cognitive and behavioral therapy, medications,
and alternative eastern therapies.
Cognitive and behavioral therapies are a form of counseling that teaches anxiety
patients techniques for gaining control over their thoughts and concerns. In particular, they are
trained to distinguish actual concerns from potential or even fictitious thoughts that are
unrealistic. This is done through the analysis of their thoughts, behaviors, and feelings and the
recognition of patterns within themselves that lead to destructive or disadvantageous
outcomes. Once they are able to recognize the destructive thoughts and behaviors, the
patients are then able to more easily modify their thoughts and behaviors to cope with their
condition (Deacon and Abramowitz 2004). For anxieties which refer to specific phobias,
typically exposure therapy is the treatment of choice. With this psychotherapy, anxiety
patients are slowly exposed to concepts and pieces of their phobia, in hopes of gradually
habituating them to it (Gunter and Whittal 2010). For instance, if a person was afraid of flying
in planes, exposure therapy might first start with showing the people pictures of a plane, or
10

persons inside a plane smiling and laughing. Next, they could have the person pack a bag as if
they were getting ready for an actual trip. Additional steps could be driving to the airport, and
then sitting at the gate. Eventually, through gradual habituation and training the person is
eventually able to confront their phobia of flying.
In addition to behavioral- and psycho-therapies, medications such as benzodiazepines
(BZDs), selective serotonin reuptake inhibitors (SSRIs), azapirones, beta blockers,
antipsychotics, and pregabalins are also a common choice for many health care professionals in
the treatment of anxiety.
BZDs, which are the most commonly prescribed medication for the treatment of acute
anxiety (Stahl and Ph 2002), are GABAergic allosteric modulators first discovered in the 1960s
that bind to the GABA receptor, and potentiate the action of GABA. This GABAergic
potentiation then causes increased flow of Cl- through the GABA receptor, and subsequent
hyperpolarization and inhibition of the cell (Argyropoulos et al. 2001). Some of the most
commonly prescribed BDZs are Alrpazolam (Xanax), Lorazepam (Ativan), Clonazepam
(Klonopin), and Diazepam (Valium) (Stahl and Ph 2002). BZDs are most commonly prescribed
for short term anxiety, and tend to work rather well (Davidson 2009); however, the benefits of
BZDs are often outweighed by their strong negative side effects. While BZDs work well at short
term relief of anxiety, they are not suited for chronic administration. In particular, BZDs are
plagued by their strong side effects, which can include sedation and psychomotor impairment.
In addition, BZDs can also be addictive, which can lead to withdrawal symptoms and rebound
symptoms further complicating the mental health of the individual (Argyropoulos et al. 2001;
Sramek et al. 2002; Stahl and Ph 2002; Katzman 2009). Interestingly, BZDs have also developed
11

a strong negative stigma which prevents or makes most patients uncomfortable with their use
which can lead to decreased patience compliance (Sramek et al. 2002).
While BZDs are most adept at treating immediate relief of anxiety, the general opinion
of clinicians suggests that the ultimate goal of treatment is long term relief of anxiety-like
symptoms. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine
reuptake inhibitors (SNRIs) have become the recommended first-line therapies for the long
term maintenance and treatment of GAD. SSRIs inhibit the serotonin transporter which is
responsible for the reuptake of serotonin from the synaptic cleft back into the neuronal soma
for reuse and degradation. Thus, SSRIs potentiate the effects of serotonin by prolonging its
persistence in the synaptic cleft. SNRIs are similar, however, they are able to inhibit the uptake
of both serotonin and norepinephrine. Some of the most commonly prescribes SSRIs and SNRIs
for anxiety are as follows: paroxetine (Paxil®) 12% of anxiety cases, venlafaxine (Effexor®) 6%,
sertraline (Zoloft®) 5%, citalopram (Celexa®, or the newer escitalopram known as Lexapro®) 4%,
and Nefazodone (Serzone®) 4% (Stahl and Ph 2002).
While SSRIs and SNRIs are better at the long-term treatment of anxiety over BZDs, they
are not without a plethora of side effects and drawbacks of their own. Perhaps one of the
initial major drawbacks is their therapeutic lag, with an onset of about 1-2 weeks. In addition,
there are many common side effects of these drugs such as nausea, vomiting, headaches,
insomnia, diarrhea, weight change, paradoxical behavior (i.e., increased depression or anxiety)
suicidal thoughts, and dizziness just to name a few. These drugs also need to be tapered off,
and even with this gradual weaning of the drug withdrawal can still manifest and persist for 1-2
weeks (Argyropoulos et al. 2001).
12

A third class of molecules which can be used to treat GAD are known as azapirones.
Azapirones have a different mechanism of action than BZDs and SSRIs, and work by acting as a
partial agonist for the 5-HT1A receptor (Chessick et al. 2006). The serotonin 5-HT1A receptor is
Gαi bound which leads to inhibition of adenylyl cyclase and subsequently decreased levels of
cAMP (Olivier et al. 1999). Buspirone (Buspar®) is the most commonly used azapirone, and is
prescribed in about 9% of the drug treatments for GAD (Stahl and Ph 2002). While buspirone
has its advantages over BZDs in that it is not associated with withdrawal, addiction, or
tolerance, it has its own list of drawbacks and side effects. Buspirone for one has a long
therapeutic lag of 2-3 weeks, thus it is not optimal for the treatment of acute anxiety (Katzman
2009). It has also been reported by anxiety patients that buspirone is not as effective as BZDs
and SSRIs/SNRIs and thus patient compliance is lower with buspirone treatment (Chessick et al.
2006). In addition, buspirone has a short half-life which can require patients to take it more
often throughout the day which can decrease patient compliance (Sramek et al. 2002).
Some less commonly used drugs for GAD include beta adrenergic blockers and
antipsychotics. Beta blockers are more often used for panic disorders, specific phobias, and
social anxiety — mainly because they are able to control the peripheral somatic symptoms that
are the defining characteristics of many of these disorders; however, in certain cases they are
sometimes prescribed for the treatment of GAD (Argyropoulos et al. 2001). Antipsychotics are
also sometimes used for the treatment of nonpsychotic anxiety, however their use is
controversial and still somewhat inconsistent and reserved as a last resort option for individuals
that have experienced treatment-resistant GAD. Antipsychotics can be broken down into
“typical” antipsychotics (TAPs) which are the first generation drugs developed in the 1950s that
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are dopamine receptor antagonists, and “atypical” antipsychotics (AAPs) developed in the
1990s which tend to have less motor side effects than their predecessors. Trifluoperazine,
which is a first-generation TAP, has FDA approval for use in GAD. In addition the TAP
perphenazine has also been used in combination with amitriptyline, a tricyclic antidepressant
(Pies 2009), for the treatment of GAD. While the TAPs have FDA approved labeling for the
treatment of GAD, that does not exclude the use of AAPs by clinicians for the use of GAD as an
off label use (Summary 2011). There are some studies showing that these AAPs may have an
effect on anxiety (Pies 2009), whereas other studies have yielded inconsistent results on the
legitimacy of using AAPs as a therapy for treatment-resistant GAD (Lorenz et al. 2010). Thus
more studies are needed on the use of AAPs in anxiety before FDA approval is obtained.
There are other drugs that are also approved for anxiety in other parts of the world that
are not approved by the FDA in America. One such drug is known as Pregabalin. Pregabalin is a
high-affinity ligand for the alpha-2-delta subunit of the P/Q calcium channel. While it has been
shown that this ligand can be mildly effective in the treatment of GAD, it is currently not
approved in the United States (Katzman 2009; Baldwin et al. 2013). An additional drug
approved in Europe and Australia is Agomelatine. Agomelatine is a melatonin receptor 1
agonist that has been reported to decrease the severity of anxiety-like symptoms as measured
by the HAM-A in several clinical trials (Stein et al. 2008; Stein et al. 2013; Stein et al. 2014).
While Agomelatine was tested in the United States, it did not make it through clinical trials due
to weak efficacy and possible liver damage
(http://clinicaltrials.gov/ct2/show/results/NCT00411099).
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Lastly, there are also alternative forms of medicine available for anxiety such as
acupuncture, yoga, and promoting a healthier lifestyle through exercise and proper nutrition. It
was found in a placebo-controlled, randomized, double-blind study that after 10 sessions of
verum acupuncture, patients showed a significant improvement in anxiety as measured
through the CGI (Eich et al. 2000). While the mechanisms for how acupuncture works are
unknown, it has been suggested that acupuncture may work through activation of the
parasympathetic nervous system via activation of the vagus nerve. Supporting this theory are
studies which examined acupuncture in the large intestine 4 regions (LI4) vs a placebo
acupuncture at a non-essential sham area. This study used both quantitative
electroencephalography (qEEG) and heart rate variability (HRV) to examine how these
treatments affected EEG brain patterns and the low frequency/high frequency ratio of the
heart. They found LI4 acupuncture had a significant effect on the α1 waves of the brain, and
also significantly increased the HF ratio of the heart and decreased heart rate a minute after
simulation, indicating an activation of the vagus nerve (Streitberger et al. 2008). This agrees
with with clinical studies showing that vagus nerve stimulation is an effective treatment for
mood disorders (George et al. 2007).
Yoga is another possible alternative treatment for anxiety, however, the results on the
efficacy of yoga in lowering clinical severity are inconsistent and need further clarification
(Kirkwood et al. 2005). Exercise and healthy lifestyle choices are a broad treatment which
generally improve most diseases in a non-specific manner. Indeed, it has been shown that
exercise can help make people more resilient to stress and reduce anxiety-like symptoms
(Broman-Fulks et al. 2004). However, exercise is not without its own downfalls as a treatment
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option, as this is a difficult life transition for many individuals to implement due to time or
willpower, and may also be difficult for certain individuals with impairments that may prohibit
them from active exercise (Salmon 2001; Ströhle 2009).
1.2.2. Treatments for depression. The treatments for depression are remarkably similar to those used
for the treatments of GAD, and this should come as no surprise in that depression exhibits a
63% comorbidity with GAD (Davidson 2009). The first-generation antidepressants were the
monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants (TCAs). These drugs were
both discovered around the 1950s, and soon thereafter became strongly used in the treatment
of depression. The first MAOI, iproniazid, was initially developed for tuberculosis when it was
noticed that patients taking this experienced improvements in their mood and heightened
euphoria. The MAOIs work by inhibiting the monoamine oxidase enzyme, which is an enzyme
responsible for the breakdown of serotonin and norepinephrine. The TCAs followed shortly
thereafter with the discovery of imipramine (Tofranil) which was originally developed for
schizophrenia (Lieberman 2003). The TCAs work by increasing levels of norepinephrine and
serotonin in the synaptic cleft. While these antidepressants were hailed as “miracle drugs”
when they were first discovered, their use has greatly diminished over the last decades due to
safety concerns.
The SSRIs and SNRIs which are the newer “second -generation” line of antidepressants
began to make an appearance in the late 1980s, and began replacing the TCAs and MAOIs in
terms of first-line therapy choice (Olfson and Marcus 2009). SSRIs are the most commonly
prescribed medication for depression and have been estimated to account for nearly 70% of all
antidepressant drugs (Olfson and Marcus 2009). The most commonly prescribed SSRIs are
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paroxetine (Paxil), sertraline (Zoloft), citalopram (Celexa), and fluoxetine (Prozac). Although all
of these SSRIs work by inhibiting serotonin uptake, they have differences in their
pharmacokinetic profile which may offer unique pros and cons for each drug over one another
(Magni et al. 2013). As mentioned previously, while SSRIs and SNRIs are much safer than the
first-generation MOIs/TCAs, they have a long therapeutic lag and a plethora of side effects.
It is very common for patients not to respond to monotherapy for depression, in fact
typically only 30% of people respond to one therapy. Thus depression typically requires much
experimentation and combination-adjunctive therapy (Khan et al. 2012). It has been found that
combining both cognitive therapy and or multiple drug therapies typically delivers the highest
success rate (Shelton et al. 2010). This lack of success with single antidepressant efficacy is
known as “treatment-resistant depression” (TRD). While the pharmacotherapies and
nonpharmacological therapies such as cognitive therapy are typically first-line treatments,
there are several options available to clinicians for those who are resistant. Electroconvulsive
therapy (ECT) is one of the oldest therapies for depression, and is still used today albeit as a late
choice therapeutic for TRD. While ECT is highly effective and works in about 50-60% of
treatment-resistant cases, it has a highly negative stigma in our society. In addition, the main
side effects of ECT are cognitive impairment with loss of memory as the most common deficit
observed (Lisanby 2007; Shelton et al. 2010). Vagus nerve stimulation (VNS) is an additional
option for TRD. Originally used for the treatment of epilepsy, it was approved for the
treatment of depression in 2005 by the FDA. Initial studies have shown promising results for
VNS, but since this is an invasive procedure it is only used for severe TRD. Side effects of VNS
can include neck pain, difficult breathing, hoarseness, changes in voice, and coughing (George
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et al. 2007; Shelton et al. 2010). Transcranial magnetic stimulation (TMS) is a newer technique
approved by the FDA in 2008 that has gained traction as a possible treatment for depression.
TMS essentially is able to stimulate and “turn on” cortical networks through application of a
magnetic field delivered from a coil placed above regions in the skull. Initial studies suggest
TMR can be highly effective in TRD with success rates as high as 65%, however more evidence is
needed as the results are still inconsistent (Shelton et al. 2010). TMS is also regarded as being a
safe treatment with very few side effects. There has been one reported case of seizures after
TMS (Conca et al. 2000) and also several observances of induced mania (Sakkas et al. 2003).
Similar to anxiety, there are also many alternative therapies that can be used for
depression such as yoga, acupuncture, and exercise. As described previously, these therapies
have been shown to work in certain individuals, but seem to be hampered by lack of consistent
evidence-based efficacy and/or difficulty with patient compliance (Eich et al. 2000; Salmon
2001; Broman-Fulks et al. 2004; Kirkwood et al. 2005; Streitberger et al. 2008; Wang et al. 2008;
Ströhle 2009).

1.2.3. Treatments for memory disorders. While progress has been made in the development of
therapeutics for anxiety and depression, there has been a significant bottleneck in the
development of AD-related therapeutics. Currently there are only 5 approved drugs for AD in
two different classes: the anticholinesterases (donepezil, Aricept®; galantamine, Reminyl®;
rivastigmine, Exelon®; and tacrine, Cognex®), and the NMDA receptor antagonists (memantine,
Namenda®) (Raina et al. 2008).
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The anticholinesterase class of drugs is based upon the cholinergic hypothesis of AD,
and the observation that acetylcholine levels are lowered in the brain of AD patients (Richter et
al. 1980). It is believed that if these acetylcholine levels are restored, then the cognitive deficits
associated with the disease could possibly be attenuated (Lleó et al. 2006). The cholinergic
class of drugs raises acetylcholine levels by inhibiting the enzyme acetylcholinesterase, which is
the enzyme that is responsible for the catabolism of acetylcholine. These various cholinergic
drugs while having the same target, have different pharmacokinetics which is the main
distinction between one another (Lleó et al. 2006). The first cholinergic drug ever approved for
AD was tacrine (Crismon 1994). Since then, tacrine has been slowly replaced by the newer
cholinergics most likely due to increased safety concerns, as tacrine was shown to have possible
hepatotoxicity issues. While these cholinergic drugs are commonly prescribed by clinicians,
they normally do so because of lack of options. Studies have shown while the clinical results
seen by these drugs are significant over placebo, they are clinically very mild and demonstrate
only small improvements in the MMSE and ADAS-cog (Lleó et al. 2006; Raina et al. 2008).
The second class of drugs approved for use in AD is the NMDA receptor antagonist
memantine. The therapeutic rationale behind NMDA antagonism has its roots in the belief that
glutamatergic excitotoxicity may be occurring in AD (Molinuevo et al.; Danysz et al. 2000; Hynd
et al. 2004). While glutamate is an essential neurotransmitter in the brain and instrumental in
the mediation of memory, too much of it can be damaging to neurons. It is believed that in the
AD brain this excitotoxicity may be occurring, thus memantine is believed to be able to stop this
excitotoxicity through antagonism of NMDA-glutamate receptors. While the theory behind this
is sound, the clinical efficacy of memantine has fallen short; it has been shown that memantine
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has inconsistent and very mild, albeit significant effects on cognitive symptoms (Lleó et al.
2006; Raina et al. 2008). Even though memantine may show a slight improvement on cognitive
symptoms, it has been shown to have little efficacy in halting the course of AD pathology.
1.3. Obesity
Obesity is an additional disorder that has risen to the ranks of a national pandemic,
affecting ~30% of the population, and costing the United States over 150 billion dollars a year
(Ogden et al. 2012). Obesity is also major risk factor for leading causes of death such as
cardiovascular disease, stroke, and diabetes. Obesity is defined as a body mass index of over
30 kg/m2, or a body fat percentage over 25%. Sadly, obesity is one of the most preventable
disorders in the country; however, due to cultural changes such as poor dietary choices,
sedentary living, and overabundance of affordable, easily obtainable trans-saturated fats, it has
become a pandemic to which our country is currently losing. These statements are made evident
by the fact that zero states have been able to reduce their obesity rate below 15% as set forth in
the United States healthy people 2010 pledge (Services 2010).
While at first one may think that obesity is significantly removed from mental illness
because it is a peripheral disorder, recent research has shown that anxiety, depression, and
obesity are not mutually exclusive, but may in fact be very closely related to each other. Obesity
has been strongly linked to anxiety and depression, and exhibits a high comorbidity (Simon et al.
2007); however, a causal relationship between the two is still unclear. Due to the complicated
mechanisms of these disorders it is still unknown which one is the catalyst, or if they are mutually
influential; this complex relationship needs further characterization
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1.3.2. Treatments for obesity. There are currently many different therapeutics that can be used to
combat obesity. The most obvious of these therapies and the first choice of many doctors is
through exercise and proper nutrition. Diet and physical activity are typically recommended for
people that have milder forms of obesity with a BMI in a range of 25-30 (Fisher and Schauer
2002). However, exercise and proper nutrition are often very difficult for most individuals and
have a very low success and compliance rate. In addition, there is a high remission rate in those
that are successful due to the body trying to reset itself to its “programmed weight”.
An additional approach to combat obesity is through pharmacological intervention.
Pharmacological interventions are not normally used until individuals have reached a BMI of
around 30 (Fisher and Schauer 2002). There are several therapeutic strategies an anti-obesity
drug can follow such as appetite suppression (anorectic), interference with absorption of
nutrients, or increased metabolism of nutrients (Klonoff and Greenway 2008). While there
were 4 FDA-approved drugs for the labeled treatment of obesity: Orlistat, diethylpropion,
phentermine-topiramate, and sibutramine (Campfield 1998; Moyers 2005; Eckel 2008;
Ioannides-Demos et al. 2011), recently the FDA has pulled many of the drugs for safety
concerns (Colman et al. 2012). Currently orlistat is the only FDA approved drug for obesity on
the market (Colman et al. 2012). Orlistat is a pancreatic lipase inhibitor that works by
preventing the absorption of fat in the small intestine. Orlistat has been shown to be mildly
effective in reducing weight, and is relatively safe. Since orlistat prevents the absorption of fat,
the major side effects are fecal incontinence, flatulation, and oily discharge from the bowels
(Campfield 1998; Moyers 2005; Eckel 2008; Ioannides-Demos et al. 2011).
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While the FDA now only has 1 approved drug for obesity, that does not prevent
clinicians from using other drugs to combat obesity in “off label” uses. One such example is the
use of bupropion (Wellbutrin®) as an off target therapy for obesity (Moyers 2005). In addition,
there are also clinical trials underway for new obesity-fighting drugs such as Zonisamide. So far
Zonisamide has shown promise (Ioannides-Demos et al. 2011; Nguyen et al. 2013; Gadde et al.
2014), and if approved may be combined with bupropion to form a synergistic novel drug that
could combat obesity.
The large list of non FDA approved obesity drugs such as diethylpropion, phenterminetopiramate, sibutramine, rimonabant, Lorcaserin, and amfepramone are representative of the
difficulty in developing a safe anti-obesity agent. It is interesting to note that all of the drugs
are “more of the same”, in other words they all repeat the same fate of previous drugs that
have failed and continue to follow the same strategies mentioned before. This may be due to
“herd theory”, in which researchers continue to focus on what is known, as opposed to thinking
out of the box and identifying novel drug targets and treatment strategies.
A last line approach for morbidly obese patients with a BMI of 30 and higher (but
typically in the 35 and higher range) is bariatric surgery (Fisher and Schauer 2002). The most
common of the bariatric surgeries in the United States is the Roux-en-Y gastric bypass surgery.
This surgery has fallen into favor over the older vertical banded gastroplasty due to the fact it
both limits the amount of food an individual can eat, and the amount of nutrients that can be
extracted from the food. These surgeries are often used as a last resort after lifestyle changes
and pharmacotherapies have both failed and/or are not possible (Fisher and Schauer 2002).
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1.4. Need for new therapeutics in cognitive disorders and obesity.
As shown, there are many current options clinicians have for the treatment of cognitive
disorders; however most of these treatments are plagued by a plethora of side effects. In
regards to anxiety, BZDs can cause addiction and sedation, and SSRIs/SNRIs may elicit nausea,
weight change, paradoxical behavior, and suicidal thoughts. While the BZDs have incredible
short term efficacy, they are inept at treating anxiety long term, and while the SSRIs/SNRIs and
azapirones may be better at long term chronic use, they lack the ability to affect anxiety acutely.
In addition, alternative therapies are safe and generally well tolerated but lack strong efficacy
and consistent clinical evidence, and are difficult for patients to implement and subsequently
have low compliance. Thus, there is yet to be a drug with the ability to modulate anxiety in both
the short term and long term, without major side effects. Considering anxiety is the most
common psychiatric disorder on the planet, the lack of an efficient therapeutic represents a
considerable gap in the knowledge, and an aim for future drug development. While there has
been progress made in the field of antidepressants, like anxiety, there is yet to be a panacea-like
drug. The SSRIs/SNRIs have a long therapeutic lag, and are only effective in a small percentage
of individuals. The older TCAs/MOIs are dampened by their dangerous side effects, and the
therapies for TRD are often invasive and costly. TRD is very common, and as mentioned only
about 30% of individuals respond to the first monotherapy. Thus, like anxiety, there is a strong
need to develop novel antidepressants which are more effective with less side effects. AD
therapeutics have had far less success than their anxiety and depression counterparts. While
there are 5 currently approved therapies for AD, they lack significant clinical efficacy. Obesity
therapeutics have met with even greater failure. Orlistat is the only currently approved
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pharmaceutical therapy for obesity in the United States, as the FDA has pulled many drugs off
the markets due to safety concerns.
Due to the inherent drawbacks in all of the previously mentioned disorders, there remains a
strong need to develop novel therapeutics to combat these diseases.
1.5. Phosphodiesterase 4 and downstream signaling as a potential therapeutic for cognitive
disorders, and obesity
1.5.1. Rationale for Phosphodiesterase-4 as a novel target for cognition and obesity. As
previously mentioned, there is a strong need to develop novel therapeutics to combat cognitive
disorders and obesity. However, before a therapeutic can be designed, a molecular target first
needs to be identified. Phosphodiesterases (PDEs) may represent a future novel target for
therapies aimed at combatting cognitive disorders and obesity. PDEs are a “super family” of 11
enzyme families (PDE1-11) responsible for the hydrolysis of the secondary messengers cyclic
AMP (cAMP) and cyclic GMP (cGMP) (Zhang et al. 2002; Houslay and Adams 2003; Conti et al.
2003a; O’Donnell and Zhang 2004). The different families of PDEs are encoded through
different genes and have unique protein structures, binding partners, tissue expression, and
inhibitor specificities. In addition, PDE families can also be distinguished by their specificity for
cyclic nucleotide degradation (Maurice et al. 2014). For example, some PDEs are capable of
hydrolyzing both cAMP and cGMP (PDE1, 2, 3, 10, and 11), while others can only hydrolyze
cAMP (PDE4, 7, and 8) or cGMP (PDE5, 6, and 9) (Menniti et al. 2006; Omori and Kotera 2007).
Over the years PDEs have gained significant attention as novel drug targets (Zhang et al. 2006;
Menniti et al. 2006; Richter et al. 2013). There are currently several FDA-approved PDE
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inhibitors: sildenafil (Viagra), a PDE5 inhibitor used for impotence (Smith et al. 2013),
roflumilast (Daxas) and apremilast (Otezla) , PDE4 inhibitors for the treatment of chronic
obstructive pulmonary disease (COPD) (Pinner et al. 2012) and psoriatic arthritis (Varada et al.
2014) respectively, and cilostazol (Pletal), a PDE3 inhibitor used for intermittent claudication
(Cone et al. 1999). While there are 11 families of PDEs, PDE4 has garnered significant interest

Fig. 1.1 – Simpliﬁed schematic of the cAMP/CREB signaling pathway. Abbreviations : Glutamate (Glu), 2-amino3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid (AMPA), N-methyl-D-aspartate (NMDA) receptor,
depolarization (depol.), rat-sarcoma protein (RAS), ribosomal s6 kinase (RS6), RNA polymerase II (RNA Pol II),
CREB binding protein (CBP), G-protein coupled receptor signaling (GPCR), norepinephrine (NE), acetylcholine
(ACh), protein kinase A (PKA), adenylyl cyclase (AC), mitogen-activated protein-kinase (MAPK), receptor tyrosine
kinase b (TrkB), brain-derived neurotrophic-factor (BDNF)
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in cognitive and obesity research due to its high affinity for cAMP, and strong expression in the
brain (Houslay and Adams 2003; Conti et al. 2003a; Zhang 2009), in particular regions involved
with anxiety, depression, memory, and obesity, such as the amygdala, prefrontal cortex,
hippocampus, nucleus accumbens, and hypothalamus (Cherry and Davis 1999; McPhee et al.
2001; Lakics et al. 2010; Johansson et al. 2012). Since the main function of PDE4 is the
degradation of cAMP, the cAMP signaling pathway will be explored in the following section.
1.5.2. The cAMP-signaling pathway. cAMP and cGMP are the main second messengers of the cell, and
are instrumental in orchestrating many molecular events and downstream cascades such as
cAMP response element binding protein (CREB) (figure 1.1). Multiple pathways are capable of
converging to produce the initiation of the cAMP pathway and initiate gene transcription. For
standard G-protein coupled receptor signaling, binding of a ligand such as norepinephrine or
acetylcholine to their respective Gαs coupled receptor, liberates the αs-subunit from the
inhibitory β and γ subunitis. The activated αs-subunit then in turn activates adenylyl cyclase (AC).
AC catalyzes the formation of cAMP from ATP in an energy dependent manner. Cyclic AMP
activates protein kinase A (PKA) by binding to the regulatory subunits and relieving autoinhibition. Once activated, the catalytic units of PKA travel to the nucleus and phosphorylate the
transcription factor CREB.
Glutamatergic signaling is also capable of activating the cAMP pathway through AMPA
and NMDA receptors. Once the NMDA receptor is activated by AMPA induced depolarization,
binding of glutamate, and expulsion of the magnesium ion, calcium ﬂow through the NMDA
receptor is capable of activating certain AC isoforms sensitive to calcium (I, III, VIII) which results
in subsequent phosphorylation of CREB (Hanoune and Defer 2001). CREB is a very important
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transcription factor that has been implicated in many cognitive processes and also obesity, and
could be a potential downstream target of altered PDE signaling (Hansen and Zhang 2013). In
certain instances, tyrosine kinases involved with MAPK signaling can also activate the cAMPsignaling pathway (Gerits et al. 2008), and subsequent activation of CREB.
1.5.3. CREB and downstream trancription products. CREB is a ~46 kDa size protein residing in the
nucleus that is capable of being activated by multiple pathways including cAMP/PKA-mediated
signaling, Ca2+/CamKII/IV, or the MAPK/ERK pathway (Figure 1.1). There are two main subtypes
of CREB (CREB1 and CREB2), and three different isoforms of CREB1 that are produced by
alternative splicing (α, β, and δ). Of interest for this discussion is CREB1, which will be referred
to hereafter simply as CREB. CREB is a transcription factor (Montminy MR 1987) whose function
in “learning” was first discovered in studies of Aplysia (Dash et al. 1990), and has now been
extensively implicated in learning and memory (Bourtchuladze et al. 1994), long term
potentiation (LTP) (Impey et al. 1996), neuro-protection (Ao et al. 2006), anxiety (Blundell and
Adamec 2006; Adamec et al. 2011), depression (Muschamp et al. 2011), and obesity (Reusch et
al. 2000; Qi et al. 2009).

Upon activation, CREB is phosphorylated at its serine 133 residue, dimerizes with
another pCREB, binds its cAMP respone element (CRE) site on the promoter DNA via a leucine
zipper domain, and then recruits several co-activator proteins to assist with transcription.
Among the co-activator proteins recruited are CREB binding protein (CBP), p300, and RNA
polymerase II. CBP and p300 both contain histone acetyl-transferase ability, which relaxes the
chromatin structure from histones, making it more readily available for transcription by Pol II
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(Johannessen et al. 2004; Carlezon et al. 2005). In regards to CREB kinetics, it is important to
note that CREB may already be dimerized and bound to CRE sites under basal conditions, and
simply becomes activated during phosphorylation. This is a controversial area and still needs
further clarification (Cha-molstad et al. 2004).

There are also several proteins worth mentioning that are capable of modifying CREB
activity. The phosphatases PP1 and PP2A are both involved with negative regulation of CREB,
and have been shown to terminate its signaling (Wadzinski et al. 1993; Bito et al. 1996). In
addition, the inducible cAMP early repressor (ICER), which is derived from the cAMP-responsive
element modulator (CREM) gene via an alternative intrinsic promoter, is capable of inhibiting
CREB activity by binding to the CRE domain. ICER is able to do this without activation of
transcription because it lacks the activation and kinase inducible domains present on CREB,
thus ICER competes with CREB for the CRE sites and acts as a negative regulator. Interestingly,
the alternative intrinsic promoter for ICER contains a CRE site, and ICER transcription itself is
driven by pCREB activation. Thus CREB is able to succinctly regulate its own activity by driving
transcription of its repressors (Lonze and Ginty 2002; Borlikova and Endo 2009).

The CREB transcriptome has currently been identified at approximately 1,663 CRE
targets in humans and 1,349 possible binding sites in mice, though the actual functional
transcriptome differs drastically depending on the tissue and cell type (Conkright et al. 2003).
Some important transcripts downstream of CREB include brain derived neurotrophic factor
(BDNF) and c-FOS. BDNF is a neurotrophic molecule that has extensively been linked to LTP
(Patterson et al. 1996; Korte et al. 1996; Figurov et al. 1996; Korte et al. 1998; Xu et al. 2000;
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Patterson et al. 2001) learning and memory (Hall et al. 2000), anxiety (Lakshminarasimhan and
Chattarji 2012) and obesity (Schwartz and Mobbs 2012). BDNF binds to the TrkB receptor (Xu
et al. 2000) and can be released from neurons upon stimulation (Androutsellis-Theotokis et al.
1996; Kojima et al. 2001). The relationship between CREB and BDNF is cyclical; BDNF activates
CREB transcription (Finkbeiner et al. 1997), which in turn increases BDNF transcription via the
CRE promoter (Tao et al. 1998; Shieh and Ghosh 1999).

1.5.4. Background of PDE4.
The PDE4 enzyme is
unique from other PDEs
in that it contains two
upstream conserved
regions (UCRs) termed
UCR1 and UCR2 located
towards the N’ terminus region. These UCR

Figure 1.2. PDE4 protein-domain structure, (taken from Zhang
2009, Curr. Pharm. Design)

regions play an important
regulatory role in the enzyme, and have also been shown to be very important for intracellular
targeting (Jang et al. 2010). Downstream towards the C’- terminus lies the catalytic domain of
the PDE4 enzyme which is responsible for the hydrolysis of cAMP to 5’-AMP (Saldou et al. 1998;
Houslay and Adams 2003; Conti et al. 2003a; Zhang 2009; Houslay 2010).
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PDE4 was first biochemically characterized as an enzyme capable of cAMP
phosphodiesterase activity from rat liver plasma membranes (Marchmont and Houslay 1980);
however, its involvement in cognition and behavior was first identified through mutations in
the Drosophila melanogaster dunce PDE4D gene which led to deficient cAMP-specific PDE
activity and abnormal memory (Kauvar 1982; Qui et al. 1991). PDE4 was later discovered in
both rats (Davis et al. 1989; Swinnen et al. 1989) and humans (Bolger et al. 1993) to consist of a
small family of similar enzymes encoded through 4 different genes, which are now referred to
as PDE4-A, B, C, and D (Reeves et al. 1987; Wang et al. 1997; Houslay and Adams 2003;
O’Donnell and Zhang 2004). These PDE4 subtypes are not expressed equally throughout the
body, as PDE4C has been shown to be largely deficient in the brain (Cherry and Davis 1999;
Perez-Torres et al. 2000; Lakics et al. 2010). Thus, in regards to cognitive research PDE4-A, B,
and D are the predominant subtypes which are now focused on (Zhang 2009).
In addition to the individual PDE4 subtypes, there are also multiple PDE4 splice variants,
which can be produced from alternative promoters and splicing. Up to 25 different PDE4 splice
variants have been identified to date, including 6 PDE4A splice variants, 5 PDE4B variants, 3
PDE4C variants, and 11 PDE4D variants (Bolger et al. 1996; Bolger et al. 1997; Huston et al.
1997; Sullivan et al. 1998; Rena et al. 2001; Miró et al. 2002; Shepherd et al. 2003; Bolger et al.
2003b; Wallace et al. 2005; Richter et al. 2005; Chandrasekaran et al. 2008; Mackenzie et al.
2008; Zhang 2009). This alternative splicing results in the formation of different length PDE4s,
which have come to be classified as long form, short form, super-short form, and dead-short
form (figure 1.2). Long-form PDEs are full length and contain no truncation, short forms lack a
UCR1 region, super-short forms lack a UCR1 and have a truncated UCR2, and dead-short lack
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both UCR regions and also contain a truncated catalytic domain (O’Donnell and Zhang 2004;
Zhang 2009; Richter et al. 2013). Interestingly, this alternative splicing has been shown to be
increased in mammals and humans, suggesting that the increasing complexity of nonredundant PDE4 variants observed in humans parallels the increasing levels of brain function
(Johnson et al. 2010).
1.5.5. History of PDE4 as a cognitive therapeutic: pitfalls, promises, and layers of complexity.
The idea of using PDE4 as a target for psychiatric illness is not a novel one. Since PDE4 was first
discovered, it was found shortly thereafter that the broad PDE4 inhibitor rolipram significantly
improved memory (Randt et al. 1982; Imanishi et al. 1997; Egawa et al. 1997; Barad et al. 1998),
and reversed depressive-like behavior in rodents (Wachtel 1983; Wachtel and Schneider 1986).
Because of these initial findings, rolipram made it to clinical trials as a potential antidepressant
and showed both promising (Zeller et al. 1984; Guiot-Goffioul et al. 1987; Laux et al. 1988) and
inconsistent results (Bertolino et al. 1988). However, it was soon discovered that rolipram had
a major flaw; several studies began confirming that rolipram induced severe nausea and emesis
(Hebenstreit et al. 1989; Scott et al. 1991), and the idea of rolipram as a therapeutic for
depression began to fade. Interestingly, the PDE4 inhibitor roflumilast is currently approved for
COPD, and able to avoid the side effects plagued by rolipram. The main reason for the lack of
side effects however is most likely due to the low blood-brain barrier permeability of
roflumilast, indicating that the area postrema is never activated.
The failure of rolipram in clinical trials leads to an important question, why was rolipram
destined to fail? It has since been discovered that PDE4 is highly expressed in the area
postrema (Cherry and Davis 1999) which is the emetic center of the brain (Mori et al. 2010).
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Inhibition of the PDE4 in this region “activates” the area postrema, and produces the emetic
response typical of rolipram (Heaslip and Evans 1995; Robichaud et al. 2001; Richter et al.
2013).
The failed attempts of rolipram in clinical trials (and subsequent characterization of the

Figure 1.3. Layers of PDE4 complexity. When considering PDE4 as a therapeutic target, there are varying
layers of complexity that need to be overcome. First, PDE4 is expressed in many regions in the periphery in
addition to the CNS that could lead to off target side effects. PDE4 also has multiple subtypes and splice
variants that have differential expression in brain tissues. Complicating this further is the fact that cAMP
signaling has different roles in various brain regions. Finally, within these brain regions and neurons, the
multiple splice variants have different binding partners, and different targeting and intracellular expression
which leads to compartmentalization of cAMP signaling. These multiple “layers of PDE4 complexity” could
result in non-redundant functional roles for each PDE4 variant which makes broad PDE4 inhibition as a future
therapeutic a difficult therapeutic. PDE4 subtype and splice-variant specific therapeutics are more likely to
be successful in the future, however much more work is still needed to develop these therapies.

mechanisms) has shed light onto the “layers of PDE4 complexity” (Figure 1.3). The first
32

complexity of PDE4 is that it has multiple subtypes as described previously (PDE4A, B, C, and D).
In addition, these subtypes are encoded through different genes, PDE4 then has multiple splice
variants within each subtype produced through alternative splicing and promoters. These
individual splice variants of PDE4 are then differentially expressed throughout the body, both
peripherally and centrally, as well as in discrete regions even within the brain. The level of
complexity is increased by the fact that cAMP has various functions in different regions of the
body. Lastly, even within discrete brain regions and individual neurons themselves, PDE4 splice
variants have different binding partners and intracellular expression which leads to unique
targeting of the splice variants, and subsequent compartmentalization or “pools” of cAMP that
have contrasting functions (Houslay and Adams 2003; Baillie 2009; Blackman et al. 2011).
Because of this incredible complexity, focus in the PDE4 field has shifted from PDE4 in general,
to the characterization and targeting of specific PDE4 subtypes in hopes of circumventing the
side effects of broad PDE4 inhibition. The PDE4 subtypes and splice variants will be talked
about in the following sections.
1.5.4. PDE4D. One of the main PDE4 subtypes is PDE4D, which has the most splice variants of the PDE4
family, and is the most studied. PDE4D currently has 11 splice variants termed PDE4D1-11;
PDE4D1/2 are short forms, PDE4D6 is super short, and the remaining splice variants are all full
length PDE4 proteins (Bolger et al. 1997; Conti et al. 2003a; O’Donnell and Zhang 2004; Cheung
et al. 2007; Houslay et al. 2007; Chandrasekaran et al. 2008; Lynex et al. 2008; Zhang 2009;
Maurice et al. 2014).
PDE4D has a diffuse pattern of expression throughout the brain, with noticeable
expression in the hippocampus, cortex, thalamus, area postrema, periaqueductal grey, brain
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stem, and cerebellum (Engels et al. 1995; Cherry and Davis 1999; Perez-Torres et al. 2000;
McPhee et al. 2001; D’Sa et al. 2005; Lakics et al. 2010; Johansson et al. 2012; Kelly et al. 2014).
In addition, PDE4D also has specific binding partners such as myomegalin protein (Verde et al.
2001), beta arrestins (Baillie et al. 2003; Bolger et al. 2003a; Lynch et al. 2005; Baillie et al. 2007;
Lynch et al. 2007; Li et al. 2009a), RACK1 (Conti et al. 2003a), SH3-domain regions (Beard et al.
1999) and the A-Kinase anchoring proteins (AKAPS), Erk, and exchange protein directly activated
by cAMP (EPAC) (Dodge et al. 2001; Dodge-Kafka et al. 2005).
PDE4D has also been extensively studied using PDE4D KO mice designed by homolgous
recombination (Jin et al. 2005b) and through viral manipulation. Through these techniques it has
been found that PDE4D KO mice exhibit improved memory (Li et al. 2011), increased synaptic
long-term potentiation (LTP) (Rutten et al. 2008), reduced levels of depressive-like behavior
(Zhang et al. 2002);, elevated neurogenesis (Zhang et al. 2002; Li et al. 2011), and impaired
growth and fertility (Jin et al. 1999) This is supported by studies showing that RNAi or inhibitors
with relatively high selectivity for PDE4D also produce memory-enhancing effects (Burgin et al.
2010; Li et al. 2011; Bruno et al. 2011), reversed memory deficits induced by beta-amyloid
peptide 1-42 (Zhang et al. 2014, and/or antidepressant activity (Wang et al. 2013). However,
PDE4D KO also causes emetic-like behavior, the major side effect of PDE4 inhibitors (Robichaud
et al. 2002a; Robichaud et al. 2002b). These studies have greatly illustrated the role that PDE4D
plays in behavior. We are now aware that the PDE4D subtype plays a strong role in memory,
probably due to its high expression in the hippocampus. PDE4D is also one of the major subtypes
in the mediation of depressive-like behavior, as mice deficient in PDE4D were less sensitive to
the anti-depressant effect of rolipram.

Unfortunately, the PDE4D subtype is also the main
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mediator of the emetic side effects seen with rolipram. Upon further evaluation this data makes
sense, since PDE4D has the highest expression of any of the PDE4 subtypes in the area postrema
(Cherry and Davis 1999; Mori et al. 2010). Recently, PDE4D specific allosteric modulators have
also become avaiable which only “partially” inhibit PDE4D; this study found that they were able
to reduce the emetic effects of PDE4D inhibition as measured through duration of anesthesia
induced by ketamine/xylazine (Robichaud et al. 2002a; Robichaud et al. 2002b) but maintian the
nootropic effect (Burgin et al. 2010). While it was previously very difficult to make a PDE4
subtype-specific inhibitor, x-ray structure of the PDE4 proteins (Wang et al. 2007a) revealed a
phenylalanine-196 residue that was only present on PDE4D, which was able to be targeted by
allosteric modulators (Burgin et al. 2010). The memory enhancing effects of PDE4D dysruption
have also been supported by more recent relatively selective PDE4D inhibitors (Bruno et al. 2011;
Sierksma et al. 2013)
PDE4D single nucleotide polymorphisms (SNP) have also been associated with stroke (He
et al. 2013; Liu et al. 2013b; Liu et al. 2013a; Heyer et al. 2013), however the results have been
inconsistent (Shao et al. 2014). One study has confirmed that the PDE4D SNP83 is higher in Asian
and Chinese populations, but not among Caucasians by conducting a meta-analysis with a much
larger sample size (Yan et al. 2014). PDE4D mutations have also been associated with skeletal
dysplasia and intellectual disability (Lindstrand et al. 2014).
While we are beginning to understand the role PDE4D plays in behavior, much additional
research is needed to further characterize the role the PDE4D subtype, and more importantly, its
splice variants, play in behavior and cognition.
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1.5.5. PDE4B. PDE4B has 5 splice variants identified PDE4B1-5; PDE4B1, 3, and 4 are long isoforms,
PDE4B2 is short, and PDE4B5 is super short (Bolger et al. 1997; Conti et al. 2003a; O’Donnell and
Zhang 2004; Cheung et al. 2007; Houslay et al. 2007; Chandrasekaran et al. 2008; Lynex et al.
2008; Zhang 2009).
While most of the PDE4 subtype expression patterns overlap a good bit and vary with
different studies, PDE4B is unique in the fact that it is consistently the highest PDE4 subtype
expressed in the striatum, globus-pallidus, nucleus accumbens, hypothalamus, and amygdala
(Engels et al. 1995; Cherry and Davis 1999; Perez-Torres et al. 2000; McPhee et al. 2001; D’Sa et
al. 2005; Lakics et al. 2010; Johansson et al. 2012; Kelly et al. 2014). PDE4B is also unique in that
mutations in PDE4B are strongly believed to play a role in schizophrenia through its interaction
with disrupted in schizophrenia 1 protein (DISC1) (Millar et al. 2005; Fatemi et al. 2008; Numata
et al. 2008; Numata et al. 2009; Kähler et al. 2010). Interestingly, it was observed that this PDE4B
mutation results in a decrease of PDE4B expression (Fatemi et al. 2008).
PDE4B KO mice studies have shown that PDE4B is the main PDE4 subtype responsible for
the release of tumor necrosis factor-α (TNF-α) in response to lipopolysaccharide injections (LPS).
In particular, these studies found that PDE4B KO reduced the amount of TNF-α released in
response to LPS, while PDE4A and PDE4D did not play a role (Jin and Conti 2002; Jin et al. 2005a).
Thus, it appears that PDE4B may be one of the main PDE4 subtypes involved with mediation of
the immune response, as PDE4B has also been shown to be involved with Amyloid beta induced
microglia activation (Sebastiani et al. 2006). Additional PDE4B KO studies have shown that PDE4B
KO is anxiogenic and increases corticosterone levels, and also decreases depressive-like behavior
in mice (Zhang et al. 2008)
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Until very recently, PDE4B specific inhibitors were not available. However, Burgin and
colleagues have recently designed PDE4B allosteric modulators (Burgin et al. 2010) and a
separate group has made PDE4B inhibitors using a different approach by targeting the Leu674
residue in PDE4B region CR3 (Fox et al. 2014).
While we are beginning to understand the role PDE4B plays in behavior, additional
research is needed to further characterize the role that the PDE4B subtype, and more
importantly, its splice variants, play in behavior and cognition.
1.5.6. PDE4A. The PDE4A subtype has 6 splice variants; PDE4A1 is short (Sullivan et al. 1998), PDE4A7
is the dead-short form (Horton et al. 1995; Johnston et al. 2004), and PDE4A5 (McPhee et al.
1995), PDE4A8 (Bolger et al. 1996), PDE4A10 (Rena et al. 2001), and PDE4A11 (Wallace et al.
2005) are long forms (Bolger et al. 1997; Owens et al. 1997; Conti et al. 2003a; O’Donnell and
Zhang 2004; Cheung et al. 2007; Houslay et al. 2007; Chandrasekaran et al. 2008; Lynex et al.
2008; Zhang 2009). The broad PDE4A subtype has been found to be strongly expressed in the
olfactory bulbs, deep layers of the cortex, amygdala, hypothalamus, hippocampus, piriform
cortex, and cerebellum (Engels et al. 1995; Cherry and Davis 1999; Perez-Torres et al. 2000;
McPhee et al. 2001; D’Sa et al. 2005; Lakics et al. 2010; Johansson et al. 2012; Kelly et al. 2014).
Interestingly, PDE4A is one of the few PDE4 subtypes where differential splice-variant
expression patterns have been looked at. McPhee and colleagues found that the long PDE4A5/10
isoforms were present throughout most of the cortex, CA1, and CA2 in overlapping patterns,
however, PDE4A10 was present in the islands of Calleja while PDE4A1 and PDE4A5 were not. In
addition, PDE4A5 and PDEA10 were present in the medial nucleus of the amygdala, while PDE4A1
37

expression was absent. PDE4A1 had a different expression pattern than the longer isoforms,
with very strong expression in the glomerular layer of the olfactory bulbs, CA3 of the
hippocampus, the cerebellum, and low staining in the brain stem (McPhee et al. 2001). D’Sa and
colleagues also looked at PDE4A expression, and observed slightly different patterns.
Specifically, they saw that PDE4A1 was high in the medial septum, diagonal band, olfactory
system, hippocampus and cerebellum; PDE4A5 was highly expressed in the olfactory nuclei, deep
cortical layers, and the DG and CA1 of the hippocampus; PDE4A10 was highly expressed in the
DG and CA1, and PDE4A8 expression was absent in the brain (D’Sa et al. 2005)
PDE4A1 has also been found to be unique, in that it is inserted into lipid bilayers through
a TAPAS-1 (tryptophan anchoring phosphatidic acid selective-binding domain 1); these bilayers
are typically found on golgi that traffic out to the membrane (Baillie et al. 2002). PDE4A5 is
unique from the remaining subtypes in that it can interact with SH3 domains on proteins through
its N’ Terminal region (O’Connell et al. 1996). This SH3 binding plays a significant role in the
targeting of PDE4A5, which has been found to be expressed in perinuclear regions, and also
within membrane ruffles (Beard et al. 2002). This expression pattern of PDE4A5 has been shown
to be disrupted in apoptotic cells by cleavage of caspase 3 at its SH3 binding sites, and
overexpression of PDE4A5 protects against apoptosis (Huston et al. 2000). Another unique trait
of PDE4A5 is that it can bind to an immunophilin known as XAP2 which partially inhibits the
enzyme up to 60%, and increases its sensitivity to rolipram (Bolger et al. 2003b). Interestingly,
PDE4A can also be activated by the P70S6 kinase in adipocytes during adipogenesis, which
suggests it could play a role in obesity (MacKenzie et al. 1998). Lastly, PDE4A5 is the only
member of the PDE4A family which can be phosphorylated by MAPK which tends to attenuate
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its activation by PKA (MacKenzie et al. 2011). The PDE4A7 and PDE4A8 splice variants are
exclusively found in the testis in rodents, however in humans PDE4A8 has undergone an
evolutionary change which causes it to be expressed in the brain (Mackenzie et al. 2008).
While there has been some progress on the functional roles of PDE4B and D in behavior,
the role that PDE4A plays in behavior is largely unknown. While PDE4A KO mice have been
examined for olfaction, no changes were found and behavior was not tested (Cygnar and Zhao
2009). Interestingly, antidepressant treatment has been shown to increase PDE4A expression in
limbic and cortical regions (Ye et al. 2000; D’Sa et al. 2005). It has also been shown that PDE4A
activity is significantly reduced in obese individuals (Omar et al. 2011) and mice (Greene et al.
2009), suggesting that altered PDE4A activity could be a mechanism for obesity-related
pathology. Additional evidence has shown that sleep-deprivation-induced memory deficits
correlate with impaired cAMP signaling, increased PDE4A5 expression, and elevated PDE4
activity (Vecsey et al. 2009). These studies, along with the fact that PDE4A expression is observed
in the prefrontal cortex, hypothalamus, amygdala, and striatum, (memory, anxiety, depression,
and obesity-related brain regions) indicate that PDE4A could play a significant role in the
mediation of anxiety, memory, depression, and/or obesity. This gap in the knowledge represents
a significant opportunity for study, as the characterization of PDE4A in these states could have
profound impacts on the development of future drug targets, and the PDE4 field; this led to the
purpose of this dissertation and following studies, which will be covered in the next section.
1.6. Summary and Objectives
The progress in developing PDE4 targeted therapeutics for cognitive disorders has been
unsuccessful, and been stagnant over much of recent history. This is mostly due to the strong
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side effects associated with broad PDE4 inhibition such as nausea and emesis. In addition,
pharmaceutical treatments for obesity have largely failed, and recently many of the formerly
FDA approved obesolytics were pulled due to safety concerns, leaving Orlistat as the only FDA
approved therapy.
Recently, the specific targeting of individual PDE4 subtypes or splice variants has begun to
shed light into their incredible complexity and differential functional roles. Through the use of
KO mice and viral manipulation, it has been shown that PDE4D is involved with the main emetic
response of rolipram, and is also involved with antidepressant-like behavior and memory.
PDE4B KO mice have shown an anxiogenic profile, elevated corticosterone, decreased immune
response, and decreased depressive-like behavior. However, the functional role that PDE4A
plays in behavior and obesity is still unknown.
As mentioned, anxiety, depression, AD, and obesity are considerable public health threats
in need of novel therapeutics with high efficacy and low side effects. Interestingly, it has also
been shown that depression, anxiety, and obesity are highly co-morbid. However, the causal
relationship between these three is still currently unknown. Due to the fact PDE4A is strongly
expressed in regions of the brain important for anxiety, depression, AD, and obesity, it is
possible that PDE4A could be a novel target for future therapeutics aimed at combatting these
diseases. Thus the objective of this study was to investigate the role that PDE4A plays in
behavior and obesity through the following aims:
1.

Characterize the functional role that PDE4A plays in behavior through the use of PDE4A
KO mice.
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PDE4A KO mice will be generated through homologous recombination and provided by
our collaborator Dr. Marco Conti of UCSF. The role of PDE4A in behavior will then be
characterized through a large battery of behavioral tests looking at activity, nociception,
visual acuity, social interaction, memory, anxiety, and depression. In addition,
biochemical tests will also be performed to look at hormone levels in the body, as well as
molecular changes to the cAMP/PDE signaling pathway.
2.

To Characterize the functional role that PDE4A plays in obesity through the use of
PDE4A KO mice

The relationship between obesity and PDE4A will be examined through PDE4A KO mice.
PDE4A KO mice (see aim 1) will be carefully monitored for body weight, changes in
activity, food consumption, and differences in metabolic hormones.

Our central hypothesis for the study is that PDE4A KO will be Nootropic, obesogenic, and
anxiogenic.

2.2. Contributions
Portions of this background were taken from a previously published review (Hansen and
Zhang 2013).
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Chapter 2

PDE4A KO and behavior
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2.1. Introduction
Cognitive disorders such as anxiety, depression, and pathological/non pathological
memory loss are growing pandemics in this country that represent considerable public health
threats. From this list of public mental health threats, anxiety disorders in particular are the
most common affecting upwards of 20% of the population and costing the American economy
over 50 billion dollars a year (Greenberg et al. 1999).
Anxiety has been described as “a psychological, physiological, and behavioral state
induced in animals and humans by a threat to well-being and survival, either actual or potential”
(Steimer 2011). Because of this, it can be argued that anxiogenic behaviors were essential to the
survival of species, and probably evolved as an adaptive trait in early animals. However, in
pathological anxiety there seems to be a dysadaptation, in which animals or humans are unable
to appropriately adjust to varying degrees of stress whether actual or perceived. While there are
treatments for anxiety such as therapy (cognitive behavioral therapy, exposure therapy),
medications

(benzodiazepines,

selective

serotonin

reuptake

inhibitors-SSRIs),

and

complementary alternative therapies (yoga, acupuncture), anxiety still remains a prominent
problem. Although anxiolytics are effective in alleviating anxiety, they come so with a price. Due
to their general sedative properties benzodiazepines can result in severe drowsiness, leading to
problems of impaired coordination and blunted attention. This side effect becomes increasingly
problematic when related to employment and the work force, as anxiolytics can significantly
impair the ability of a person to effectively maintain the level of concentration needed to
maintain workplace composure. Benzodiazepines can even result in severe addiction, nausea,
personality changes, aggression, depression, memory impairment, and paradoxical reactions
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resulting in increased anxiety. In addition, SSRIs have a list of unwanted side effects such as
severe nauseas and diarrhea, rapid weight changes, insomnia, renal failure, cognitive disorders,
and even increased risk of depression and suicide in certain individuals. SSRI use is also dampened
by the fact that they may take weeks or months to take effect, and are ineffective in a large
percentage of individuals (Bandelow et al. 2013).
The plethora of side effects induced by anxiolytics is most likely due to the very broad
mechanism by which they act. Benzodiazepines work by enhancing GABAergic transmission;
while SSRIs work by inhibiting the serotonin transporter and globally increasing the amount of
extracellular serotonin. In addition to being expressed in anxiety-related brain regions, GABA
and serotonin receptors are highly expressed throughout the body which is involved in their
many off target side effects (Akinci and Schofield 1999; Barnes and Neumaier 2011). Thus,
anxiolytics are limited by their inherent lack of specificity to anxiogenic brain regions and the
broad mechanisms by which they achieve their effects. Because of this, there is a strong need to
develop novel anxiolytics that are able to act in a more specific manner with fewer side effects
than those that currently hinder modern anxiolytics. One possible candidate target for the
development of new therapies is the phosphodiesterase (PDE) super family (Menniti et al. 2006;
Zhang 2009).
PDEs are a “super family” of 11 smaller families of enzymes responsible for the hydrolysis
of the secondary messengers cAMP and cGMP (Zhang et al. 2002; Houslay and Adams 2003; Conti
et al. 2003a; O’Donnell and Zhang 2004). The different families of PDEs are encoded through
different genes and have unique protein structures, binding partners, tissue expression, and
inhibitor specificities. In addition, PDE families can also be distinguished by their specificity for
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cyclic nucleotide degradation. For example, some PDEs are capable of hydrolyzing both cGMP
and cAMP (PDEs 1,2,3,10,11), some PDEs can only hydrolyze cGMP (PDEs 5,6,9), while others can
only hydrolyze cAMP (PDEs 4,7,8) (Menniti et al. 2006; Omori and Kotera 2007).
Over the years PDEs have gained significant interest as novel drug targets due to their
vast differences in tissue expression (which gives them increased specificity), and also the
power that they control over intracellular signaling (Zhang et al. 2006). There are currently
several classes of FDA approved PDE inhibitors such as Sildenafil, which is a PDE5 inhibitor that
works on cGMP levels in the corpus cavernosum to increase smooth muscle dilation (Smith et
al. 2013), and PDE4 inhibitors such as roflumilast for the treatment of chronic obstructive
pulmonary disease (COPD) (Pinner et al. 2012). PDE4 inhibitors may also have important
actions in areas other than the periphery. There has been much investigation into the field of
PDE4 and cognition mediated by the central nervous system.
PDE4 is of particular interest with relation to cognitive disorders due to its high affinity
for cAMP and strong expression in multiple regions such as the hippocampus, amygdala, and
nucleus accumbens which are important for memory, anxiety, and depression, respectively
(Cherry and Davis 1999; McPhee et al. 2001). PDE4 and its subtypes are distinguished from the
11 other families of PDEs by their unique protein structure. This structure consists of two
regions termed UCR1 and UCR2 (upstream conserved regions) towards the N-’ terminus of the
enzyme. Downstream towards the C-’ terminus is the other main domain of the protein
consisting of the catalytic unit. In addition, alternative splicing can result in the formation of
different length PDE4s, which can be classified as: long form, short form, super short form, and
dead-short form(Conti et al. 2003b; Houslay and Adams 2003). Long form PDE4s have all the
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domains intact, short forms have a missing UCR1 region, super short forms have a missing UCR1
and truncated UCR2, and dead-short forms are missing both UCR regions and also have a
truncated catalytic unit rendering them functionally silent (O’Donnell and Zhang 2004; Zhang
2009).
PDE4 has four subtypes (A, B, C, and D), of which only PDE4C is not strongly expressed in
the brain (Cherry and Davis 1999). Because of this, the main focus of PDE4 in regards to
cognition has been on subtypes A, B, and D. These subtypes are distinguished from one another
by the fact they are encoded by separate genes and contain different N’ terminus
domains(Conti et al. 2003b; Houslay and Adams 2003; O’Donnell and Zhang 2004; Zhang 2009).
In addition, the level of complexity is increased with multiple splice variants belonging to each
subtype due to alternative splicing and multiple promoter sites.
Until recently, the functional role of PDE4 subtypes in the CNS was unknown. However,
through the use of gene knockout (KO) mice, viral vector-mediated RNA interference (RNAi),
and recent PDE4-subtype selective inhibitors, we have now been able to study the functional
role of individual PDE4 subtypes in the CNS. It has been found that PDE4D KO or inhibition
improves memory (Burgin et al. 2010; Li et al. 2011; Bruno et al. 2011), increases synaptic LTP
(Rutten et al. 2008), reduces levels of depressive-like behavior ( Zhang et al. 2002; Wang et al.
2013), and increases adult neurogenesis (Li et al. 2011). However, PDE4D KO also causes
emetic-like behavior, the major side effect of PDE4 inhibitors (Robichaud et al. 2002a;
Robichaud et al. 2002b). In addition, PDE4B KO mice exhibit anxiety-like behavior in multiple
behavioral tests and also show elevated plasma corticosterone (Zhang et al. 2008). While
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progress has been made in our understanding of PDE4B and PDE4D, the functional role that
PDE4A plays in the mediation of behavior has yet to be studied.
The PDE4A subtype can be further broken down into six splice variants: PDE4A1, A5, A7,
A8, A10 and A11. These splice variants are comprised of different lengths (A1=short form,
A7=dead form, A5, A8, A10, A11=long forms), and are also expressed differentially in the body.
(McPhee et al. 1995; Sullivan et al. 1998; Richter et al. 2001; McPhee et al. 2001; Cherry and
Pho 2002; Bolger et al. 2003b; D’Sa et al. 2005). The expression pattern of PDE4A splice
variants is complex, and can vary from rodent to human. For example, the PDE4A8 variant is
found primarily in the testis of rodents, while in humans it has gained an extended N-’ terminal
region and is also expressed in skeletal muscle and the brain (Mackenzie et al. 2008). PDE4A7 is
widely expressed, but is functionally silent (Johnston et al. 2004) . The long isoforms PDE4A5/10
are found in most of the same brain regions such as the striatum, thalamus, hippocampus (CA1,
CA2, DG), medial nucleus of amygdala, olfactory nuclei, and deep cortical layers; however, one
noted exception is expression of PDE4A10 in the islands of Calleja in which PDE4A5 expression
is absent. PDE4A1 exhibits a similar expression profile, but it is not expressed in the amygdala,
while it was very strongly expressed in the cerebellum where most of the longer isoforms are
absent (McPhee et al. 2001). While these few studies are starting to characterize the
expression of PDE4A splice variants and function at the molecular level, much more work is
needed to characterize the functional role of PDE4A in mediating cognition and behavior. Thus
the goal of this study was to characterize the role that PDE4A plays in cognition through the use
of PDE4A KO mice and a battery of behavioral tests.
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2.2. Materials and Methods.
Animals
All procedures were approved by the Animal Care and Use Committee of West Virginia
University Health Sciences Center and performed according to the recommendations of the NIH
Guide for the Care and Use of Laboratory Animals 7th edition (NIH Publications No. 80-23,
revised 1996). Adult male PDE4A KO mice on C57 background were generated by homologous
recombination and heterozygote breeding as described previously (Jin et al. 1999; Jin and Conti
2002; Ariga et al. 2004; Jin et al. 2005a; Bruss et al. 2008; Jin et al. 2010). In brief, the PDE4A
gene was disrupted through replacement of a 3 kb region encoding exons 10-14 using a PGKhrpt cassette in the reversed orientation via homologous recombination. These PDE4A KO mice
are commercially available through the Mutant Mouse Regional Resource Centers which also
provides additional details on their generation (MMRRC; http://www.mmrrc.org; Stock number
034793-UCD). Age-matched (4-8 months) wild-type (WT) mice (C57BL/6J) of the same
background were used in this study. All genotyping was confirmed by Southern blot analysis
with tissues obtained via tail clipping and subsequent detection of genomic DNA. Animals were
housed in groups of 2-5 per cage (Allentown XJ cage, 12.5” length x 6” width x 5” height, 75
square inches of floor space) in a light (12 h on, 12 h off; lights on at 0600 h) and temperature
controlled room (22-23 C). Water and food were available ad libitum.
Behavioral Paradigm
Two batches of adult WT and PDE4A KO mice were used to investigate the role of PDE4A on
behavior and biochemistry. Batch 1 consisted of two groups of WT (n = 9) and PDE4A KO (n =
9), while batch 2 consisted of 5 mice each for WT and PDE4A KO (Figure 1). The data from
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the two batches were combined for statistical analysis. All behavioral tests were performed from
0900-1500 hours. The experimenter was blinded to the genotype of the animals, and animal
testing order was randomized daily to reduce subjective bias. The battery was organized so that
tests with minimal stress were performed first and tests with maximal stress and stimuli
performed last (Figure 2.1). Before the testing paradigm began, animals were habituated (HAB)
for 1 week by being transferred from the housing room to the testing room, being allowed to sit
for 45 min, gently handled, and then returned to the housing room. Testing for both batches
started at 4 months of age and then progressively took place until 8 months of age following the
protocol laid out in figure 1. All animals were housed in groups of 2-5 other than 1 WT mouse
in batch 2, which was single housed (the behavioral data still fell within the group mean and was
included in the analysis). Mice were allowed a minimum of 45 min to habituate to the testing
room after transfer from the housing room before behavioral tests were initiated. All chambers
and testing apparatuses used were cleaned with 70% alcohol between animals to avoid any
confounding effects of olfaction on behavior.

Figure 2.1. Behavioral Paradigm. Two batches of mice were used. Each batch consisted of two groups of PDE4A
knockout (KO) and wild-type (WT) mice (n = 9 mice/group for batch 1 and n = 5/group for batch 2). The battery of
behavioral tests was performed during days 1-34 in the following order: Habituation (HAB), open field (OF), object
recognition (OR), elevated-plus-maze (EPM), hole-board (HB), light-dark-transition (LDT), forced-swim test (FST),
tail-suspension test (TST), Morris Water Maze (MWM), step-through passive-avoidance (STPA), noveltysuppressed-feeding test (NSF), emesis test (EME).
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Measurement of Locomotor Activity
Mice were placed into individual PAS automated open field chambers (San Diego Instruments
San Diego, CA). The number of light beam crossings for locomotor activity (horizontal crossings)
and rears (vertical crossings) were recorded and averaged over six 5-min intervals (Hu et al.
2011).
Anxiety-like behavior Tests
Elevated plus-maze test. Mice were placed individually in the center of a plus-shaped maze (40
cm above the floor) facing an open arm. The number of entries (with all four paws in) and time
spent in both open arms (30 x 5 cm) and enclosed arms (30 x 5 x 15 cm high) were recorded for
5 min. The level of anxiety-like behavior was determined by the percentage entries into open
arms, and percentage time spent in open arms, which were calculated by: Open arm entry (%) =
number of open arm entries/total number of arm entries x 100; Open arm time (%) = time (s)
spent in open arms/total time (s) in all arms x 100 (Li et al. 2009b).
Light-dark transition test. Mice were individually placed in the dark compartment (15 x 23 cm)
of a light-dark chamber. Anxiety-like behavior was determined by the following measures
recorded for 5 min: the latency to cross through the hole (8 x 6 cm) into the light compartment
(30 x 23 cm, illuminated with a 60-W bulb positioned 50 cm above), the time spent in the light
compartment, and the number of transitions defined as the number of crossings from the dark
compartment to the light side (Zhang et al. 2008).
Holeboard test. Mice were individually placed in the center of an open Plexiglas box (40 x 40 x 30
cm) with four holes (3 cm in diameter, 2 cm in depth) in the black floor and allowed to explore
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for 5 min. Anxiety-like behavior was measured by recording the number of head-dips into the
holes and the total time spent exploring the holes. Head dips were counted when the animal’s
head reached a depth sufficient enough to be even with its ears (Zhang et al. 2008).
Novelty suppressed feeding test. In brief, mice were deprived of food 24 h prior to the test. After
24 h of food deprivation, the mice were individually placed in the corner of a plastic open
chamber (35 x 28 x16 cm) covered by a 1-cm thick layer of wooden bedding. A pellet of food
(regular chow) was placed in the center of the floor, and a 60-watt bulb placed 50 cm above the
center of the chamber. The latency to begin to chew the pellet, time spent digging, and the total
amount of time spent eating were recorded for a total of 5 min.
Depression-like behavior Tests
Forced-swim test. Mice were individually placed in a plastic cylinder (45 cm high  20 cm
diameter) filled with water (22-23°C; 30 cm in depth) for 6 min and the duration of immobility
was recorded (Zhang et al. 2002). Immobility was defined as floating in an upright position
without additional activity other than that necessary for the animal to keep its head above water.
Fresh water was used for every other mouse.
Tail-suspension test. Mice were suspended from their tails and the duration of immobility (i.e.,
when the mouse was passively hanging and completely motionlessness) was recorded for a 6min period (Zhang et al. 2002). Mice were separated by black plastic partitions to avoid
confounding effects of neighboring behavior. The effects of conspecific vocalizations however
can’t be ruled out.
Memory Tests
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Object recognition test. This was carried out using the procedures described previously (Li et al.
2011). In brief, mice were trained over three 5-min sessions separated by 24 h to discriminate a
novel object from a familiar one in a plastic chamber (40 x 40 x 20 cm). In the first trial (T1),
animals were placed in the chamber without an object and allowed to explore and habituate to
the environment. Twenty-four hours later, animals were put back in the chamber for the training
session (T2) and exposed to two identical objects (blue Lego blocks) located in two opposite
corners of the box. The exploration time of each object was recorded to control for object and
side bias. After 24 h, mice were returned to the box to start the testing trial (T3), during which
they were exposed to a familiar object (one of the Lego blocks from day 2) and a novel object (a
red, cone-shaped, plastic glass), which was different from the familiar one in color and shape and
placed in one of the same positions as the objects in T2. The exploration time for each object (Tf
and Tn for familiar and novel objects, respectively) was recorded for determination of the
recognition index [RI = Tn/(Tn+Tf)]. Exploration was defined as facing or touching the object
(within 2 cm of the object). The chamber and objects were thoroughly cleaned with 70% alcohol
after every session to ensure olfactory cues did not play a role in the test.
Morris water-maze test. This test was used to assess spatial learning and memory following
procedures described previously (Li et al. 2011) with slight modifications. In brief, mice were
placed into a circular pool (95 cm diameter x 25 cm high) in which a circular platform (8.5 cm
diameter x 15.5 cm high) was placed. The pool was then filled with water (21 ± 1⁰C) made opaque
by the addition of powdered milk. Curtains were closed around the pool to eliminate any
extraneous distal cues, and the water level was maintained so that the platform was 1 cm above
the water. On the first day of the protocol, the visible cued-platform test was performed to
52

control for sensory/motor abilities as well as motivation to exit the pool. A small red flag was
placed on the platform and four visible cued-platform trials were run by placing the mouse at
random starting locations, in which the animal was allowed to escape by finding the platform.
The platform was placed at a new location for each trial. During the spatial acquisition trials
started the next day, the platform was submerged 1 cm below the water surface and several
extra-maze distal landmarks placed on the curtains. The mice were then trained for 15 trials over
3 days (6 trials day one, 5 trials day two, and 4 trials day three) to locate the hidden platform
from different starting points (N, S, E, W, NW, and SE). Twenty-four hours after the last training
session, a probe trial was conducted in which the platform was removed and the animals were
allowed to swim for 60 s. Assessment of spatial memory function was performed by analyzing
swim speed, the number of entries, time spent and distance traveled in the target quadrant, and
also the number of crossings over the circular area (8.5 cm in diameter) where the hidden
platform was previously located. Data was obtained using the EthoVision XT behavioral tracking
system (Noldus, The Netherlands).
Step-through passive avoidance test. This was performed following procedures described
previously (Li et al. 2011) with some modifications. In brief, the experiment was conducted using
a two-compartment Plexiglas chamber (28 x 17 x 25 cm high; ENV410B, Med Associates, St
Albans, VT), which consisted of an illuminated and darkened compartment connected via a
guillotine door and a metal grid floor connected to an isolated pulse stimulator. On the first day,
mice were placed in the illuminated compartment of the chamber and allowed to explore both
the illuminated and darkened compartments for 5 min. Twenty-four hours later during training
on day 2, each mouse was placed in the illuminated compartment, and 60 s later the door was
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opened to the dark chamber. When the mouse entered the dark chamber, the guillotine door
was closed behind it and the mouse administered a brief electric shock (0.4 mA/5 s). Twenty
seconds later the mouse was put back into the illuminated chamber, and the whole process was
repeated until the animal reached the criterion of 60 s to enter the dark chamber after the door
was opened, when the mouse was assumed to have learned the procedure and associated the
shock stimulus with the dark side. The number of shocks before reaching the criterion was
recorded to evaluate the learning ability of mice. On the testing day 24 h later, the mouse was
once again placed in the illuminated compartment with the door closed for 60 s, after which the
door was opened, and the latency for the mouse to enter the darkened compartment was
recorded for up to 300 s. No shock was administered on the testing day for animals that entered
the darkened compartment. The chamber was cleaned with 70% alcohol in between animals to
avoid any confounding effects of olfaction on memory.
Emetic-like behavior test.
This was performed as described previously (Li et al. 2011) to examine the effects of PDE4A KO
on emesis. In brief, animals were injected (i.p.) with xylazine (10 mg/kg)/ketamine (80 mg/kg).
Once the animals became ataxic, they were placed in the supine position in V-shaped metal
troughs (covered by paper towels). The duration of anesthesia was determined as the time
between the loss and return of the righting reflex; the latter was defined as when animals could
right themselves three times within 30 s after being placed on their backs.
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Determination of Corticosterone levels
Urine samples were collected by picking the mouse up and holding it until the animal urinated
on the plastic wrap. The urine was then pipetted into microcentrifuge tubes, and frozen at -80⁰C
until use. Following this procedure, the vast majority of mice urinated within 25 s, which should
have avoided any confounds of human interaction and immediate stress on corticosterone levels
(Kurien and Scofield 1999). In addition, to control for diurnal variation of corticosterone, urine
samples were collected at the same time (1200 h) every day over a course of 3 days during the
novelty suppressed feeding test (24 h before food deprivation, during food deprivation, and 24
h after food deprivation). Corticosterone levels were determined using ELISA (ABNOVA, cat#
KA0468) as per manufactures instructions
Microwave Fixation
Animals were sacrificed by microwave fixation as described previously (O’Callaghan and Sriram
2004). In brief, mice were transferred to NIOSH (Morgantown, WV) and allowed 3 h to habituate.
Animals were then placed in a water-blanketed restrainer (TAW-174 applicator head) and
immediately sacrificed in a 10 kW output Muromachi microwave applicator (Model TMW-4012C;
Stoelting, Wooddale, IL) at an exposure level of 4.0 kW for 0.9 s. The whole procedure normally
took less than 15 s to complete.
Tissue Preparation
Microwaved tissues were prepared as described previously (O’Callaghan and Sriram 2004). In
brief, microwaved brains were removed and brain specific regions dissected via coronal slices
and the use of brain specific landmarks. Brain tissues were frozen at -80⁰C until further use.
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Tissue lysate was prepared by sonicating in hot (90⁰C) 1% SDS for 15 s, and protein concentration
quantified by standard BCA protein assay kit.
Protein electrophoresis and Western blotting
These were performed following procedures described previously (Li et al. 2011). In brief, 20 µg
of hippocampal lysates were loaded onto Nupage 4-12% bis-tris gels (Life Technologies
WG1403BOX) and electrophoresis was performed at 120 v for 95 min. All chemicals and buffers
were made and used according to the Nupage Western blot protocol. After electrophoresis,
samples were transferred to PVDF membranes at 75 v on ice for 2 h. Membranes were then
blocked for 45 min at room temperature in Li-Cor blocking buffer (Li-Cor cat# 927-4000), and
incubated overnight at 4⁰C in a 1:1000 dilution of rabbit anti-PDE4A antibody (Abcam 14607) and
1:10,000 mouse anti-actin antibody (Abcam 8224) as a loading control. The next morning,
membranes were washed 4 in PBST and Li-Cor secondary fluorescent antibodies goat-anti
mouse IrDye 800CW and goat anti-rabbit 680RD were added in a 1:10,000 dilution for 40 min at
room temperature to stain for actin and PDE4A, respectively. The membranes were washed 4
more times in PBST, and then analyzed using the Odyssey infrared imaging system to check for
the presence of PDE4A and actin bands.
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Statistical Analysis
All data shown are means ± SEM, and were analyzed using the GraphPad Prism 5 software
(version 5.04). Urine ELISA corticosterone levels were plotted using 5-parametric analysis and
MasterPlex® ReaderFit: Curve-Fitting Software for ELISA (Hitachi Solutions America, Ltd.
MiraiBio Group) and then analyzed via repeated measures two-way ANOVA (2-ANOVA-R) with
Bonferroni’s post tests for multiple
comparisons; the rest of the
behavioral data were analyzed via
students two-tailed T-tests, or 2-way
ANOVA with repeated measures and
Bonferroni’s post test for the
locomotor activity/rearing and
Morris Water Maze tests. Alpha
significance was achieved with a P
value of < 0.05.
2.3. Results
2.3.1. PDE4A KO and locomotor
activity. To determine the effect of
PDE4A KO on locomotor activity,
animals were placed into a PAS-

Figure 2.2. Effects of PDE4A KO on locomotor activity and rearing in
the PAS Automated open field chamber. (a) PDE4A KO mice had no
significant difference in locomotor activity compared to WT
controls; however, they did have slightly lower activity in intervals 35. (b) PDE4A KO mice had significantly less rearing than WT mice, in
particular during the first 3 intervals. Data shown represent means
± SEM; n = 14/group; * P < 0.05, ** P < 0.01 vs. WT (two-way ANOVA
with Bonferonni multiple comparison tests).

automated open-field chamber and the number of light crossings recorded and averaged over
six 5-min intervals. There was no significant difference in locomotor activity between PDE4A KO
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mice and WT controls, although the KO mice did have a slightly lower baseline activity from 1520 min time (2-ANOVA-R: extremely significant effect of time, F(5,130) = 16.57, p < 0.0001; no
effect of genotype, F(1, 26) = 2.19, p =
0.151; no effect of genotype x time
interaction, F(5,130) = 0.75, p = 0.585;
Figure 2.2a). As an additional measure
of exploratory activity, the number of
rears was also recorded while the mice
were in the open-field chambers. It was
found that PDE4A KO mice did show

Figure 2.3. PDE4A KO and the elevated plus maze test.
PDE4A KO mice spent significantly less time in the open arms
of the EPM relative to WT controls. They also had fewer
entries into the open arm, although this was not significant

significantly lower rearing levels than WT
controls during the first 15 min of the test
(2-ANOVA-R: very significant effect of
PDE4A KO, F(1,26) = 12.77, p = 0.0014;
significant effect of time x genotype
interaction, F(5,130) = 2.36, p = 0.0438; no
effect of time, F(5,130) = 2.27, p = 0.052;
Figure 2.2b). This data indicates that while Figure 2.4. PDE4A KO and the hole board test. PDE4A KO
PDE4A KO did not induce lethargy as

mice had significantly less head dips and hole exploration
time in the HB test than WT controls.

interpreted by the lack of changes in horizontal light crossings, there was a decrease in vertical
exploratory rearing which could be indicative of an anxiogenic-like phenotype.

58

2.3.2. PDE4A KO and anxiety-like behavior.
To determine the effect of PDED4A KO on
basal levels of anxiety, PDE4A KO and WT
mice were tested in a variety of behavioral
tests for anxiety-like behaviors, including
elevated plus-maze (EPM, Figure 2.3), holeboard (HB, Figure 2.4), light-dark transition
(LDT, Figure 2.5), and novelty suppressed
feeding (NSF, Figure 2.6). In the EPM test,
PDE4A KO mice spent significantly less time in
the open arms of the maze when compared to
WT controls (t = 3.25, p = 0.003; Figure 2.3);
they also had fewer entries into the open
arms, although this was not significant (t =
0.85, p = 0.40; Figure 2.3). When tested in
the HB test, PDE4A KO mice had significantly

Figure 2.5. PDE4A KO and the light dark transition test.
PDE4A KO mice had a longer latency to enter the light
compartment, although the results were not significant.
PDE4A KO mice also spent significantly less time in the
light side, and had fewer entries into the light side
relative to WT controls in the LDT test.

fewer exploratory head- dips (t = 3.43, p = 0.0020; Figure 2.4) and also spent significantly less
time (t = 3.60, p = 0.001; Figure 2.4) exploring (head-dipping) compared to WT controls. In the
LDT test, PDE4A KO mice took longer to enter the light chamber but the results were not
significant (t=1.375, p = 0.1808, Figure 2.5a), and PDE4A KO mice spent much less time in the
light compartment (t = 3.94, p = 0.0005; Figure 2.5b) and also had significantly fewer transitions
into the light compartment (t = 3.23, p = 0.003; Figure 2.5) than the WT controls. Lastly, in the
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NSF test after 24-h food deprivation, PDE4A KO mice had a much longer latency to eat the food
placed in the center of the novel, brightly lit
chamber, relative to WT controls (t = 3.15, p
= 0.004; Figure 2.6), and also spent a
significantly longer duration of the test
burying in the bedding than WT controls (t =
3.78, p = 0.002; Figure 2.6). These results

Figure 2.6. PDE4A KO and the novelty
suppressed feeding test. PDE4A KO mice had a
significantly longer latency to eat the chow, and
also spent much more time burying than WT
controls in the NSF test.

suggest anxiogenic-like behavior in PDE4A KO
mice.

Urine corticosterone levels of PDE4A KO mice and WT controls were also analyzed
during the period of novelty
suppressed feeding. Urine was
chosen over plasma due to the
fact that urine levels are more
resistant to human handling
fluctuations which may confound
plasma levels of corticosterone
(Kurien and Scofield 1999). In
particular, we chose three time
points to observe the effect of
PDE4A KO on corticosterone

Figure 2.7. Effects of PDE4A KO on urine corticosterone levels. Urine
samples were collected from PDE4A KO and WT mice to determine the
levels of corticosterone 24h before stress (baseline), during 24 h of
stress induced by food deprivation (FD), and after stress had ended
which was 24 h after food had been restored (P24 FD). PDE4A KO
resulted in higher levels of corticosterone before and during stress
although the changes were not significant; however, 24h after the
stress had ended, PDE4A KO mice had significantly higher
corticosterone levels than WT mice. Data shown represent means ±
SEM; n = 4/group; * P < 0.05 vs. WT (2 way ANOVA with Bonferonni
multiple comparison tests).

levels: (i) before stress (before
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food was taken away), (ii) during stress (24 h
of food deprivation), and (iii) after stress (24-h
after food was restored). Interestingly, as
expected, PDE4A KO mice did have slightly
higher corticosterone levels before and during
stress; however, they unexpectedly had
significantly higher levels 24 h after the stress
was restored (2-ANOVA-R: effect of genotype
at P24 FD, F(1,6) = 4.99, p < 0.05; Figure 2.7).
These data suggest that PDE4A KO mice may
have some difficulty in terminating the
activation of the HPA axis after exposure to a
stressor when compared to WT controls.
2.3.3. PDE4A KO mice did not show significant
changes in depressive-like behavior
To identify the possible role that PDE4A plays in

Figure 2.8. Behavior of PDE4A KO and WT mice in
the FST and TST. (a) PDE4A KO resulted in a slightly
higher immobility time in the FST; however, the
change was not significant. (b) PDE4A had no effect
on immobility in the TST. Data shown represent
means ± SEM; n = 14/group (two-tailed Student’s ttest).

depressive-like behavior, we tested PDE4A KO mice in the forced swim test (FST) and tail
suspension test (TST). In the FST, PDE4A KO mice had slightly higher levels of immobility;
however, this was not significant compared to the WT controls (t = 1.74, p = 0.093; Figure 2.8a).
In the TST, PDE4A KO had no effect on total immobility time (t = 0.77, p = 0.449; Figure 2.8b).
These results indicate that PDE4A may not play a significant role in depressive-like behavior
tested using the FST and TST.
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2.3.4. PDE4A KO enhanced emotional memory but not spatial or episodic memory
To determine whether PDE4A KO produces nootropic-like effects, PDE4A KO mice were tested
in a variety of memory tests, including object
recognition (OR), Morris water-maze (MWM),
and step-through passive-avoidance (STPA)
tests. In the OR test, PDE4A KO had no effect
on novel object recognition on the testing day
relative to WT controls (t = 0.50, p = 0.625;

Figure 2.9. Effects of PDE4A KO on episodic memory
in the object recognition test. PDE4A KO mice had no
significant changes in the recognition index (RI) for
the novel object on the testing day when compared
to WT controls. Data shown represents the mean
±SEM of n=14/group (two-tailed Student’s t-test).

Figure 2.9) suggesting that PDE4A may not be
involved in mediating “episodic”-like memory.

To assess the effect of PDE4A KO on spatial memory, animals were trained in the MWM.
Unexpectedly, PDE4A KO mice had significantly longer training latencies during trials 1 through
3 of the visible-platform test (2-ANOVA-R: significant effect of Time, F(3,48) = 12.76, p < 0.0001;
significant effect of genotype, F(1,16) = 25.59, p = 0.0001; significant effect of genotype x time
interaction, F(3,48) = 5.58, p = 0.002; Figure 2.10a). During training with the invisible platform,
PDE4A KO mice also had significantly longer latencies to reach the platform on days 1 and 3
when compared to WT controls (2-ANOVA-R: extremely significant effect of time, F(2,32)
=13.84, p < 0.0001; very significant effect of genotype, F(1,16) = 9.00, p = 0.009; no significant
genotype x time interaction, F(2,32) = 0.02, p = 0.981; Figure 2.10b). However, when tested
during the probe trial, PDE4A KO mice performed similar to WT controls in regards to swim
speed (t = 1.53, p = 0.145; Figure 2.10c), distance traveled in the target quadrant (t = 1.07, p =
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0.303; Figure 2.10d), time spent in the target quadrant (t = 0.84, p = 0.415; Figure 2.10e) , and
platform region crossings (t = 0.53, p = 0.604; Figure 2.10f). These results indicate that while
PDE4A KO may produce some deficit in the learning phase of spatial memory, the retrieval

Figure 2.10. Effects of PDE4A KO on spatial memory in the Morris Water Maze (MWM) test. (a) In the cued visible
platform test, PDE4A KO mice took significantly longer to find the visible platform during the first 3 trials compared
to WT controls. (b) During the training of the hidden platform, PDE4A KO mice took significantly longer to find the
hidden platform on each training day, although the results were only significant on days 1 and 3. (c) PDE4A KO
mice had no significant difference in swim speed measured during the probe trial test. (d-f) PDE4A KO mice had no
significant difference in the % total distance in the target quadrant (TQ) (d), % time in the target quadrant (e), or
the number of crossings over the previously located platform site (f) compared to WT controls. Data shown
represent means ± SEM; n = 9/group; * P < 0.05 vs. WT (two-way ANOVA with Bonferonni multiple comparison
tests for a and b, two-tailed Student’s t-test for c-f).
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phase as interpreted by the probe trial in the MWM test seems unaffected. To determine if
deficits in vision were having a confounding effect on spatial memory training in PDE4A KO
mice, we tested PDE4A KO mice and WT controls through electroretinograms (ERGs). PDE4A
KO mice displayed no difference on the ERG in comparison to WT controls, suggesting they had
no deficits in vision (Figure 2.11.).
Lastly, to determine the effect of PDE4A KO on “emotional” memory, animals were

Figure 2.11. The effects of PDE4A KO on ERGs. To determine if PDE4A KO affected vision mice were
subjected to ERGs. PDE4A KO mice displayed no change in a- or b- waves vs. WT controls, suggesting
similar visual functions.

tested in the STPA test (Celikyurt et al. 2012). On the training day, PDE4A KO had no effect on
the number of shocks required for the animal to “learn” the association between the dark
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chamber and the electric shock (t =
1.63, p = 0.115; Figure 2.12a).
However, when tested 24 h later,
PDE4A KO animals had a significantly
longer latency to enter the dark
chamber than WT controls (t = 3.17, p =
0.004; Figure 2.12b). This data suggests
that while PDE4A KO did not affect
episodic or spatial memory retrieval as
seen in OR and MWM, emotional
memory as measured via the STPA test
was significantly improved in mice
deficient in PDE4A.
To determine if PDE4A KO
affected nociception, which could have
had a confounding effect in the STPA
test, PDE4AKO animals and WT controls

Figure 2.12. Effects of PDE4A KO on emotional memory in
the step-through passive-avoidance test. (a) PDE4A KO
mice had no significant changes compared to WT controls in
the number of trials required to learn the association
between the dark chamber and nociceptive shock (reaching
the criterion of 60 s staying in the illuminated chamber). (b)
PDE4A KO mice had a significantly longer latency to enter
the dark chamber 24 h after training compared to WT
controls. Data shown represent means ± SEM; n =
14/group; ** P < 0.01 vs. WT (two-tailed Student’s t-test).

were tested on the hot plate. PDE4 KO mice displayed no changes in nociception compared to
WT controls (Figure 2.13).
2.3.5. PDE4A KO had no effect on emetic-like behavior. To examine the effects of PDE4A
KO on emesis, we also measured the xylazine/ketamine-induced duration of anesthesia in
WT/KO mice; this is an accepted emesis screen for rodents (Robichaud et al. 2002b; Burgin et
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al. 2010; Li et al. 2011). Typically, drugs
or treatments that induce emesis cause a
decrease in the duration of anesthesia.
We observed that PDE4A KO had no
effect on the duration of anesthesia (WT
= 89.00 ± 6.49 vs. 4A KO = 95.25 ± 6.95, t
= 0.66, p = 0.521; Figure 2.14), although
rolipram-treated mice or PDE4D KO mice
showed decreased duration of

Figure 2.13. The effects of PDE4A KO on nociception. To
determine if PDE4A KO affected nociception PDE4A KO
and WT controls were tested on the hot plate. No
difference in latency to withdraw the hindlimbs were
displayed between the PDE4A KO and WT mice.

anesthesia (Li et al. 2011), suggesting
that PDE4A may not play a role in
emesis
2.3.6. Loss of PDE4A expression in
PDE4A KO mice
In addition to genotyping data (not
shown), Western blotting was
performed to confirm the
successful knockout of PDE4A in the
brains of PDE4A KO mice. Mice were

Figure 2.14. Emetic-like behavior test. PDE4A KO mice had
no changed in the duration of ketamine/xylazine induced
anesthesia, suggesting that PDE4A does not play a role in
emesis.

sacrificed via microwave fixation, decapitated, and whole hippocampi dissected. Western
blotting analysis revealed that PDE4A KO mice had a complete deficiency of PDE4A5 and
PDE4A1 in the hippocampus as compared to WT controls (Figure 2.15).
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2.3.7. PDE4A KO elevates cAMP
and pCREB levels in the brain. To
determine if PDE4A KO affected
cAMP levels and downstream
signaling, cAMP ELISAs and pCREB
western blots were performed.
PDE4A KO mice displayed
elevations of cAMP in both the
cortex and hippocampus (Figure

Figure 2.15. Confirmation of null PDE4A expression in
PDE4A KO mice. The hippocampal tissues of PDE4A KO
and WT mice were analyzed using Western blotting for
the expression of PDE4A splice variants. PDE4A KO had a
complete deficiency of PDE4A5 and PDE4A1 expression
compared to WT controls, which had strong expression of
both splice variants. This deficiency of PDE4As was not
due to human errors as PDE4A KO still had strong, equal
expression of -actin compared to WT mice.

2.16). CREB and pCREB protein
levels were also investigated in the hippocampus and cortex of PDE4A KO mice via western blot
(Figure 2.17a). pCREB levels were significantly increased in the hippocampus of PDE4A KO,
however this increase was not observed in the cerebral cortex (Figure 2.17b). In addition, to
determine if this increase was due to a basal increase of CREB expression, CREB levels were also
investigated. CREB levels were unchanged in the hippocampus (Figure 2.17c), suggesting the
increase of pCREB was due to stimulation-induced activation.

2.4. Discussion
In this study we have shown through a battery of behavioral tests that PDE4A KO results in a
strong anxiogenic profile and enhancement of emotional memory. PDE4A KO animals spent
much less time in the open arms of the EPM, displayed decreases in both head dipping and
exploration time in the HB test, had less transitions and time spent in the light chamber of the
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LDT, and had a much longer latency to eat food in addition to hyperactive digging in the NSF
test. A battery of anxiety tests was
used to ensure a true phenotype
was identified, as it has been
suggested running only one test
may not capture “trait” anxiety
(Ramos 2008; Steimer 2011). Thus,
running multiple anxiety tests
increases the chances of observing
true trait anxiety-like behavior as

Figure 2.16. cAMP levels in PDE4A KO mice. cAMP levels were
measured by ELISA in PDE4A KO and WT controls. PDE4A KO
mice displayed elevated cAMP levels in both the cerebral
cortex and the hippocampus.

opposed to a fluctuation of state anxiety which may be due to a single stressful event. In
addition to measuring behavioral correlates of anxiety, we also measured urine corticosterone
levels of PDE4A KO animals before, during, and after stress (before food deprivation, during
food deprivation, and after food deprivation of the NSF test respectively). Urine corticosterone
levels in PDE4A KO animals tended to be higher than WT before and during stress though the
difference did not reach significance; however, urine corticosterone levels were significantly
higher 24 hours after the stressor had been removed. This data suggests that PDE4A KO
animals could have a deficiency involving negative regulation of the hypothalamic-pituitary axis
(HPA), and could exhibit prolonged tonic release of corticosterone compared to WTs in
response to a stressor.
In addition to the strong anxiogenic behavioral profile observed in PDE4A KO animals, we
also observed an enhancement of “emotional” memory while other forms of memory seemed
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unaffected. In particular, PDE4A KO
animals had a significantly longer
latency to enter the dark chamber in
the testing day of STPA indicative of
an enhanced emotional memory
between the association of the dark
chamber and nociceptive electric
shock. It is important to keep in mind
that due to the fundamental
limitations of global PDE4A KO, we
were unable to determine whether
this memory enhancement was
through increased acquisition,
consolidation, or retrieval, thus
further research is needed on this
matter to elicit the specific
mechanisms involved. In contrast,

Figure 2.17. pCREB/CREB protein levels in PDE4A KO mice.
CREB/pCREB levels were measured by western blot in PDE4A
KO and WT controls. PDE4A KO mice displayed elevated
pCREB levels in the hippocampus; CREB levels were
unchanged.

when tested in the OR test which is representative of episodic memory, PDE4A KO animals
showed no improvement over WT controls. Interestingly, when testing spatial memory in the
MWM, PDE4A KO animals had significantly longer latencies on training days 1 and 3 to find the
hidden platform, but performed similarly to controls during the probe test day. This data
suggests that while the acquisition or consolidation of spatial memory may be impaired in
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PDE4A KOs, the retrieval phase seemed unaffected. In addition, PDE4A KOs also had
significantly longer times to reach the platform during the first 3 trials of the cued visible
platform test. While this data may represent a deficit in motivation to escape, it is more likely
that PDE4A KOs had deficits in other areas such as visual-spatial working memory, or visual
acuity since the latency for PDE4A KOs to reach the visible platform did improve during each
trial (suggesting that reaching it was a rewarding experience and they were motivated to
escape faster). Also, PDE4A KOs had no difference in swim velocity compared to WTs
suggesting physical limitations were not the reason for the increased latency to reach the
platform. One explanation for the attenuation in the training phase and visible platform test of
the MWM could be due to elevated levels of corticosterone and anxiety-like behavior induced
by PDE4A KO as it has been shown that both anxiety and elevated glucocorticoids can interfere
with spatial memory learning (Korte 2001; Vasconcellos et al. 2003; Shackman et al. 2006).
PDE4A KO animals showed no significant changes in behavioral depression tests, though PDE4A
KOs did tend to have higher immobility in the FST. The behavioral effects of PDE4A KO on
anxiety and emotional memory appear unrelated to sedation and lethargy as PDE4A KO
appeared to have no significant effects on locomotor ability.
While this study has suggested that PDE4A is involved with the mediation of anxiety like
behavior and emotional memory, the mechanisms through which it does so have yet to be
identified; however, there are many possibilities for how PDE4A KO could lead to anxiogenesis.
Indeed it has been shown that PDE4A is strongly expressed in brain regions important for
anxiety such as the prelimbic cortex , anterior cingulate cortex, piriform cortex, hippocampus,
and amygdala (McPhee et al. 2001). When considering the mechanisms through which PDE4A
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might mediate anxiety, alterations of cAMP levels should be at the forefront of the discussion
due to cAMP-hydrolysis being the defining characteristic of PDE4A function (Conti et al. 2003b;
Houslay and Adams 2003; Zhang 2009). Theoretically, PDE4A KO should lead to an increase of
cAMP levels in the aforementioned brain regions. In agreement, it has been shown previously
that PDE4B KO, which also results in anxiogenic like behavior, leads to increased cAMP levels in
the various brain regions in which it is expressed (Zhang et al. 2008). Increasing cAMP levels in
anxiety-related brain regions such as the medial pre-frontal cortex (mPFC), amygdala, and
hippocampus could have a significant impact on the manifestation of anxiety like behavior and
activation of the HPA axis depending on the region of interest. To better understand how
elevated cAMP levels could change anxiety like behavior, it is first important to understand the
individual roles that these brain regions play in the stress response.
The control of anxiety-like behavior is greatly mediated by a balance of mPFC and
amygdala activity in a top down vs. bottom up struggle of dominance (Hains and Arnsten 2008;
Arnsten 2009; Gamo and Arnsten 2011). It has been shown that this control is tightly
regulated, and the presumed increases in cAMP that should accompany PDE4A KO could have
significant changes on the functional and anatomical characteristics of these areas. Generally,
it is believed that under normal circumstances the mPFC plays an inhibitory role on the stress
response (Hains and Arnsten 2008; Arnsten 2009). This is thought to be through glutamatergic
projections of the mPFC to the anterior bed nucleus of the stria terminalis (aBNST), which then
sends inhibitory GABAergic projections to the periventricular nucleus (PVN) of the
hypothalamus (Radley et al. 2009; Radley and Sawchenko 2011). The PVN of the hypothalamus
is the main initiator of the HPA axis through the release of corticotrophin releasing factor (CRF)
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(Radley and Sawchenko 2011) which then stimulates release of adrenocorticotropic hormone
(ACTH) from the anterior pituitary. Once ACTH is in the blood stream, it can then stimulate
release of corticosterone from the adrenal glands (Radley et al. 2008) which in turn mediates
many of the effects of the stress response through mineralcorticoid (MR) and glucocorticoid
(GR) receptor activation (Korte 2001). Indeed, it has been shown that lesions to the mPFC can
result in elevated corticosterone probably due to reduced inhibitory tone on the HPA axis
(Brake et al. 2000; Radley et al. 2006a). In addition, it has also been shown that the mPFC
projects to the amygdala, and that lesions to the mPFC can result in increased c-fos (putative
marker for neuronal activity) expression in the medial amygdala indicative of hyperactivity
(Figueiredo et al. 2003).
While it is believed the mPFC plays an inhibitory role in the stress response, in actuality
this may be an oversimplification, as there are many conflicting reports on the effects of mPFC
lesions or inactivation. Groups have shown that lesions or inactivation of the mPFC can result
in attenuations of the stress response (less anxiety, decreased HPA activity) (Gonzalez et al.
2000; Deacon et al. 2003; Shah and Treit 2003; Shah and Treit 2004; Shah et al. 2004; SierraMercado et al. 2006) , increases in the stress response (Figueiredo et al. 2003), or no effects on
anxiety (Lacroix et al. 1998). While these results may at first seem difficult to interpret, it is
very possible that these contradictory findings may be due to inconsistencies between the
lesions of different groups targeting the entire mPFC as opposed to specific mPFC sub-regions.
Many groups have used lesions encompassing the entire mPFC, and thus have treated it as one
unitary homogenous region (Shah and Treit 2003); however, a more recent and accurate
approach suggests that the mPFC may actually have functional segregation along its dorsal72

ventral sub-regions which have contrasting roles in the mediation of the stress response
(Holmes and Wellman 2009). Radley and colleagues have provided compelling evidence for the
segregation of mPFC sub-regions in the regulation of the stress response (Radley et al. 2006a).
They have shown that lesions to the dorsal prelimbic (PL) mPFC result in an increase of c-fos
protein and CRF mRNA expression in the PVN after restraint stress compared to sham controls.
However, lesions to the ventral infralimbic (IL) mPFC had the exact opposite effect and resulted
in a decrease of c-fos protein and CRF mRNA in the PVN. In addition, the dorsal PL lesioned
group had significantly higher corticosterone levels than sham controls after restraint, while the
ventral IL lesioned group had lower corticosterone levels than sham post stress (Radley et al.
2006a). These results suggest that the dorsal PL-mPFC may play an inhibitory role, while the
ventral IL-mPFC may play an excitatory role on the HPA axis and stress response. Other groups
have made similar findings, as it has been shown that inhibiting synapses in the PL-mPFC during
restraint stress significantly increased the tachycardiac response, while inhibiting synapses in
the IL-mPFC reduced the tachycardiac response to stress (Tavares et al. 2009). These results
are not surprising, as it has been shown that the prelimbic and infralimbic regions have
significantly different connections in the brain and functional characteristics (Heidbreder and
Groenewegen 2003; Vertes 2004). It is interesting to note that PDE4A may be expressed
differently in the PL-mPFC vs the IL-mPFC (McPhee et al. 2001), identifying these brain regions
as a possible site of future investigation in regards to the mediation of anxiety by PDE4A.
During times of relaxation and normal wakefulness, the mPFC is tonically active and the
amygdala, which is one of the defining anxiety and negative emotion related brain areas, is
more hypoactive (Arnsten 2009). However, when a stressor occurs, the amygdala is activated,
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which in turn activates catecholaminergic areas in the brain stem such as the locus coeruleus
(LC) and ventral tegmental area (VTA), which are responsible for noradrenergic and
dopaminergic projections to the brain, respectively. Upon stress, axonal projections from the
LC and VTA that terminate in the mPFC release a surge of norepinephrine (NE) and dopamine
(DA) which have significant effects on the activity of mPFC pyramidal neurons (Hains and
Arnsten 2008; Arnsten 2009; Arnsten et al. 2010; Gamo and Arnsten 2011).
As previously mentioned, the dorsal PL-mPFC has been suggested to play an inhibitory
role in the mediation of anxiety-like behavior and HPA axis activity. However, the level of
inhibition from the PL-mPFC onto the HPA axis is related to the pyramidal-neuron activity
within the PL area, and this activity has been shown to be tightly regulated. The Arnsten lab has
been instrumental in characterizing the functional regulation of pyramidal dendritic spine
activity in the mPFC, and has termed this “dynamic network connectivity” as a new form of
neuroplasticity (Arnsten et al. 2010). Under normal wakeful conditions pyramidal dendritic
spine activity in the mPFC is under a fine balance of excitatory control and inhibitory “sculpting”
via α2a adrenergic receptors and dopamine D1 receptors respectively, both of which can
mediate cAMP levels in the neuron (Arnsten 2009; Arnsten et al. 2010; Arnsten 2011). In
particular, it has been shown that cAMP levels have significant control over pyramidal activity in
the PL-mPFC area via the activation of hyperpolarization-activated cyclic nucleotide-gated
(HCN) channels. Upon activation by cAMP, HCN channels open and allow the efflux of K+ ions
out of the cell, resulting in hyperpolarization, and subsequent decreased excitability of the
dendritic spines in which they are located. Normally, cAMP levels of the PL-mPFC are kept in
check by tonic low level activation of the α2A receptors, which are the high affinity NE
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receptors and Gαi coupled to suppress cAMP production. This suppression of cAMP levels
maintains the low-level activation of the PFC neurons to maintain a working memory. In
conjunction with the low levels of NE, normal low levels of dopamine also “sculpt” the neurons
and subsequent working memory by binding to D1 receptors which are Gαs coupled and
increase cAMP production. This elevation of cAMP production “sculpts out” the non-specific
neurons not being used in the maintenance of a working memory by turning them off through
activation of HCN channels. However, during stressful conditions, the high levels of DA and NE
that are released into the PL significantly increase the activity of HCN channels and reduce the
firing of all PL-mPFC pyramidal neurons (Ramos et al. 2006; Arnsten et al. 2010; Arnsten 2011;
Gamo and Arnsten 2011; Arnsten and Jin 2012). This is in party by an exaggerated activation of
D1 receptors, as well as binding of NE to lower affinity α1-adrenergic receptors which activate
the PKC pathway and subsequently produce cAMP in a Ca+ dependent manner via Ca+ sensitive
adenylyl cyclases (Hains et al. 2009). Activation of α2A receptors by Guanfacine (a selective
α2A adrenergic agonist) has been shown to reduce cAMP signaling and HCN activity, and
increase firing of PR pyramidal neurons (Ramos et al. 2006; Wang et al. 2007b). Additional
support for the importance of the LC and noradrenergic innervation in the PL-mPFC has been
shown by Radley and colleagues (Radley et al. 2008). They have shown that selective ablation
of LC-projected noradrenergic terminals in the PL-mPFC during stress reduced the amount of cFOS and CRF expression in the PVN (Radley et al. 2008). This system in the PL-mPFC is tightly
controlled, and PDE4A could be a key regulator. PDE4A KO should theoretically elevate cAMP
levels in the mPFC, activating HCN channels and reducing PL-mPFC pyramidal firing. This
decrease in PL-MPFC activity should result in suppressed inhibition of the PVN and the HPA axis,
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and could account for the elevated corticosterone and anxiogenesis observed in PDE4A KO
animals. Thus, PDE4A may be an important regulator of the activity of the PL-mPFC through
dynamic connectivity and modulation of the stress response, and could explain the strong
anxiogenic phenotype observed in PDE4A KO animals.
While it has been shown that stress and elevations in cAMP may make the mPFC
weaker, it has the exact opposite effects in the amygdala. After acute stress the mPFC shows
reduced functional activation, and after chronic stress reduced dendritic branching and length
(Radley et al. 2004; Radley et al. 2006b). Interestingly, stress results in the strengthening of the
amygdala and increased spinogensis (Vyas et al. 2002; Lakshminarasimhan and Chattarji 2012).
One possible mechanism for this increased spinogensis may be through cAMP and downstream
CREB signaling. Once cAMP is elevated in a neuron, it can then activate PKA, which relocates to
the nucleus and phosphorylates CREB (pCREB) (Finkbeiner et al. 1997; Shaywitz and Greenberg
1999; Carlezon et al. 2005; Hansen and Zhang 2013). CREB is a transcription factor which binds
cAMP response elements (CRE sites) within promoter regions of genes enhancing transcription
of the specific product (Carlezon et al. 2005; Alberini 2009). One common downstream target
of cAMP/pCREB signaling is BDNF, which has been extensively shown to increase dendritic
spinogensis (Lakshminarasimhan and Chattarji 2012; Kaneko et al. 2012; Vigers et al. 2012;
Hiester et al. 2013; Orefice et al. 2013). Interestingly, it has been found that after stress both
pCREB (Adamec et al. 2011) and BDNF (Lakshminarasimhan and Chattarji 2012) levels are
elevated in the amygdala. Since PDE4A is strongly expressed in the amygdala (McPhee et al.
2001), PDE4A KO could elevate cAMP levels in the amygdala resulting in a subsequent increase
of pCREB and BDNF-mediated spinogensis. This proposed cAMP/CREB mediated strengthening
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of the amygdala could then result in hyperactivation of the amygdala and additional inhibition
of the PL-mPFC, possibly through LC noradrenergic projections as previously mentioned.
Indeed, it has been shown that amygdala activation can decrease PL-mPFC activity (Garcia et al.
1999). In addition, it has been shown that over-expression of CREB in the amygdala increased
anxiety-like behavior in the EPM test (Wallace et al. 2004). Thus, the observed anxiogenic
phenotype and increased corticosterone observed in PDE4A KO animals may have a combined
effect of PL-mPFC hypoactivation, and amygdala hyperactivation.
The enhanced emotional memory of PDE4A KOs observed in the step-through passiveavoidance test may also be related to amygdala-based mechanisms and the subsequent
increased anxiety and corticosterone levels seen in PDE4A KO mice. Indeed it has been shown
that the amygdala plays a strong role in emotional memory (McGaugh 2004), and elevated
corticosterone causes increased amygdala-based emotional memory consolidation via
stimulation of GRs (Korte 2001; Roozendaal et al. 2009). In addition, it has also been shown
that heightened trait anxiety can lead to nootropic effects on amygdala-based fear and
emotional memory paradigms (Yen et al. 2012). Thus it may be possible that the increased
anxiety and corticosterone caused by PDE4A KO and amygdala hyperactivity could lead to
enhanced emotional memory. Elevated cAMP levels caused by PDE4A KO would almost
certainly lead to an increase of PKA activation, which has also been shown to significantly
promote the consolidation of emotional-based memory in the amygdala (Arnsten et al. 2005).
Interestingly, this could also explain why there were no improvements in the MWM, as spatial
memory has been shown to be more directly correlated to dorsal hippocampal function, as well
as to be negatively affected by anxiety and corticosterone (Korte 2001; Vasconcellos et al. 2003;
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Shackman et al. 2006). In addition, we saw no effect of PDE4A KO on the effects of OR memory
which is representative of episodic like memory (Ennaceur 2010). While the hippocampus is
important for contextual object recognition, it is not as important for non-contextual object
recognition where the objects stay in the same place and only the characteristics of the novel
object change. This paradigm has actually been shown to involve more of the perirhinal cortex
than the hippocampus (Winters et al. 2008). While PDE4A is strongly expressed in the
hippocampus, it has not yet identified as having strong expression patterns in the perirhinal
cortex and thus may explain why OR memory was unchanged (McPhee et al. 2001). It would be
interesting to see if PDE4A KO would have an effect on contextual novel object recognition in
which the locations of the objects are changed, and thus more of the hippocampus is used.
Interestingly, one study has indeed shown that PDE4A is involved with memory deprivation
following sleep deprivation (Vecsey et al. 2009)
The hippocampus has also been shown to play an important role in anxiety like
behavior. In particular, the ventral hippocampus (vHPC) has been shown to play a more
significant role in the regulation of anxiety-like behavior than the dorsal hippocampus
(Bannerman et al. 1999; Bannerman et al. 2003; Degroot and Treit 2004; Adhikari et al. 2010).
PDE4A is strongly expressed in the hippocampus (Cherry and Davis 1999; McPhee et al. 2001);
however, there has yet to be a study comparing PDE4A expression levels between the dorsal
and ventral axis. The role of the ventral hippocampus in anxiety is controversial, as studies
have shown it to play both an excitatory (Bannerman et al. 2003; McHugh et al. 2004) and
inhibitory (Radley and Sawchenko 2011) role in the stress response suggesting that there may
be additional segregation within the ventral hippocampus. It is possible that increased cAMP
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signaling due to PDE4AKO could strengthen the ventral hippocampus due to increased pCREB
and BDNF mediated spinogensis, though this is less clear than other brain regions. Theta
rhythm in the vHPC could play a significant role as well in the expression of anxiety-like
behavior. Interestingly, it has been shown that theta-rhythm in the vHPC correlates with
anxiety like behavior (Adhikari et al. 2010; Adhikari et al. 2011) and that these theta rhythms
are increased in 5-HT1A KO mice (Gordon et al. 2005) which have increased anxiety (Heisler et
al. 1998). The 5-HT1A receptor is Gi coupled, thus these mice could have elevations of cAMP
just like PDE4A KO mice could. It is possible that PDE4A KO elevated cAMP levels in the ventral
hippocampus, which resulted in increased theta rhythm and anxiogenic behavior.
There is much additional evidence suggesting cAMP levels and downstream signaling
could have significant effects on anxiety like behavior and the activation of the HPA axis and
stress response. Interestingly, it has been shown that the anxiogenic corticotropin-releasing
factor (CRF) increases cAMP signaling, and the anxiolytic neuropeptide Y decreases cAMP
signaling in an immortalized AR-5 amygdala cell line (Mulchahey et al. 1999; Sheriff et al. 2001).
In addition, it has also been shown that elevations of BDNF (which could result from increased
cAMP/pCREB inPDE4A KO) in the PVN increase CRF release, and subsequent activation of the
HPA axis (Jeanneteau et al. 2012). These studies complement our PDE4A KO behavioral data
and theory that increased cAMP signaling could cause anxiety-like behavior. In particular,
corticosterone levels in PDE4A KO animals tended to be higher before and during stress (though
the difference was not significant), however they were significantly higher 24 hours after the
stressor had been removed. Since PDE4A is the “off switch” to cAMP signaling, it is possible
that after the stressor had been removed cAMP levels remained elevated and persisted much
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longer in PDE4A KO animals than WT animals. This loss of cAMP hydrolysis could have caused
the extended release of CRF and subsequent increase of corticosterone we observed 24 hours
post stress in the PDE4A KOs.
At this point these theories are purely speculative and additional research is needed to
confirm our hypotheses. While we have suggested that increased cAMP may be responsible for
anxiety like behavior, it is important not to oversimplify this and generalize this to every area of
the brain. For example, it has been shown that PDE4D KO has antidepressant and nootropic
like properties (Zhang et al. 2002; Li et al. 2011), contrasting the anxiogenic effects observed in
PDE4B KO (Zhang et al. 2008) and PDE4A KO. While the effects of increased cAMP and pCREB
in the hippocampus are nootropic and antidepressant, increasing pCREB in the nucleus
accumbens promotes pro-depressive like behavior and anhedonia (Muschamp et al. 2011). In
addition to brain region-specific expression of PDE4 subtypes, the complexity is further
increased by splice variant expression and regions with overlapping expression patterns. The
different PDE4 subtypes and splice variants may even be having different effects within the
same neuron as compartmentalized micro-domain signaling has been shown to be extremely
important within cAMP signaling pathways (Houslay and Adams 2003; Conti et al. 2003a;
Houslay 2010). These studies point to the incredible complexity when dealing with PDE4
subtypes and cAMP/pCREB signaling, and how the same pathway can cause such contrasting
effects in different brain regions.
The results of our study show that PDE4A KO causes anxiogenesis and enhanced
emotional memory. Traditionally, most have suggested PDE4 inhibition as the most promising
therapy for possible cognitive disorders. However, we feel that this may be an
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oversimplification, and for the first time suggest PDE4A activation as a possible mechanism for
anxiolysis and the treatment of emotional memory disorders. While at this time there are no
PDE4A specific activators or inhibitors, PDE4B and D specific allosteric inhibitors have recently
become available which have much more promise than the previous broad PDE4 inhibitor
rolipram (Burgin et al. 2010). As mentioned, cAMP/pCREB signaling has vastly different effects
in different brain regions, so in order for PDE therapies to be realistic and successful in the
future, further development of PDE4 subtype-specific modulators will be needed.
While the thought of PDE4A activation for anxiolysis is a relatively novel idea, there are
data to support this theory. It has been shown that TGF-β increases PDE4A expression in the
human epithelial type II cell line A549 (Kolosionek et al. 2009), and that mice treated with TGFβ super-family members displayed anxiolytic-like behavior (Sekiyama et al. 2009). In addition,
p70S6 kinase has been shown to activate PDE4A (MacKenzie et al. 1998). Interestingly,
separate studies have shown that 5-HT can activate p70S6 kinase (Pullarkat et al. 1998). SSRIs,
which are commonly used to treat anxiety, raise extracellular 5-HT levels, and it’s possible they
may be achieving their effects through the 5-HT/p70S6 /PDE4A pathway. However since SSRIs
take several weeks for anxiolytic effects to become evident, if this pathway were involved it’s
more likely it would be through some alteration of genomic transcription than immediate
alteration of functional synaptic strength. Lastly, it has been shown that patients with major
depressive disorder (MDD) have a significant reduction of PDE4 expression in the brain (Fujita
et al. 2012) as measured by 11C-(R)-Rolipram positron emission tomography binding.
Interestingly, electroconvulsive shock therapy (ECS) in rats has also been shown to significantly
increase the amount of PDE4A, PDE4B, and PDE4D in the striatum and hippocampus (Cho et al.
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2000); unfortunately, this study did not separate the dorsal hippocampus from the ventral
hippocampus, which as mentioned previously have different roles in spatial memory and
anxiety, respectively (Degroot and Treit 2004). It is important to note that the change in
expression of PDE4 observed in MDD patients requires careful interpretation. The decreased
expression of PDE4 observed in patients with MDD is may be due to compensatory mechanisms
reacting to a decrease of global cAMP signaling (O’Donnell and Xu 2012). In addition, some
areas of the brain might benefit from PDE4 inhibition while other areas might benefit from
PDE4 activation. As mentioned earlier, PDE4D inhibition is nootropic and antidepressant
(Zhang et al. 2002; Li et al. 2011) while overexpression of PDE4D is detrimental to spatial
memory (Giorgi et al. 2004). This contrasts the effects seen in PDE4B KO and PDE4A KO, both
of which create anxiogenic like profiles (Zhang et al. 2008). Thus, there may be a need to inhibit
PDE4D for memory enhancing effects, but activate PDE4A and PDE4B for anxiolytic-like effects.
The contrasting roles that PDE4 subtypes play in behavior might account for some of the largely
inconsistent findings in regards to PDE4 inhibition and its effects on anxiety-like behavior, as
some studies have shown rolipram to be anxiolytic (Silvestre et al. 1999), while others have
shown broad PDE4 inhibition to be anxiogenic (Imaizumi et al. 1994; Heaslip and Evans 1995).
It is possible that due to the “messy” non-specific inhibition of all PDE4 subtypes under
rolipram, multiple phenotypes can emerge due to the contrasting roles the PDE4 subtypes may
play in behavior and various brain regions. This highlights the incredible complexities in the
cAMP signaling system that need to be overcome for the development of future PDE drug
targets to be specific, practical, and efficacious.
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Also, while mice deficient in PDE4D display emetic-like behavior (Robichaud et al.
2002b; Li et al. 2011), which is the major side effect of PDE4 inhibitors (Robichaud et al. 2001;
Dyke and Montana 2002; Robichaud et al. 2002a), PDE4A KO mice did not show any emesis-like
effects as demonstrated by unaltered duration of anesthesia mediated by alpha2-adrenergic
receptors, a surrogate measure of emesis in rodents (Correa-Sales et al. 1992; Robichaud et al.
2002b). The differential contributions of PDE4A and PDE4D to emetic responses appear to be
attributed to the unique distribution pattern of the PDE4 subtypes in emesis-associated brain
regions, including the area postrema and the nucleus of solitary tract, in which PDE4D is highly
expressed, but PDE4A is barely expressed (Cherry and Davis 1999; Lamontagne et al. 2001;
D’Sa et al. 2005; Mori et al. 2010).
Lastly, it is important to consider the potential confounding variables which we can’t
exclude in this study. For example, one intrinsic drawback to using global PDE4A KO is the
inability to reduce expression in a time-specific or tissue-specific manner. Since PDE4A is
knocked out from conception, we were unable to rule out the potential alterations in
development that might occur due to the knockout of PDE4A. Also, we are unable to rule out
the effects of compensatory changes from the remaining PDE4 subtypes. While previous
reports have shown no compensatory changes in PDE4-subtype KO mice (Zhang et al. 2002;
Zhang et al. 2008), the PDEs are known to be incredibly compensatory (O’Donnell and Xu 2012).
In addition, because PDE4A is expressed in the periphery as well as the CNS, we can’t exclude
the potential effects peripheral manipulation might have on the brain regions inducing
behavior. Viral-specific PDE4A knock-down of adult WT mice in discrete brain regions, or the
development of a Tet on/off Cre-lox PDE4A system would ideally be the best option for
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studying PDE4A, and development or utilization of these technologies should be used in the
future to confirm these studies and further characterize the role of PDE4A in behavior.
2.5. Summary
In conclusion we have shown for the first time that PDE4A KO results in an anxiogenic
phenotype, an increase of corticosterone post stress, and enhancement of emotional memory.
In addition, we did not notice a change in the duration of anesthesia with PDE4A KO, suggesting
it could be a possible drug target that could avoid emetic effects plaguing many PDE4 inhibitors.
Further research is needed to identify the mechanisms with which this takes place; however,
we hypothesize the effects of PDE4A KO are most likely due to elevations of cAMP levels in
anxiety-related brain regions such as the amygdala, ventral hippocampus, and the dorsal PLmPFC. PDE4A KO could result in hypoactivity of the dorsal PL-mPFC through activation of HCN
channels which should hyperpolarize the pyramidal neurons resulting in decreased firing and
suppressed inhibition of the PVN and HPA axis. In addition, elevations of cAMP levels could
strengthen the amygdala by increasing spinogensis and hyperexcitability, possibly through an
elevated pCREB-BDNF neurotrophic signaling pathway. Lastly, PDE4A KO could result in
increased hippocampal theta rhythm which has been shown to be elevated in anxiety-like
behavior. The combination of these factors would be synergistic on anxiogenesis, as there
would be decreased inhibition, and increased excitability of the stress response. These
speculations match what is seen in a clinical setting, as patients with general anxiety disorder
have been observed to have hyperactivity in the amygdala, and hypoactivity in the mPFC (Russo
et al. 2012). In addition, we suggest for the first time that specific PDE4A activation as opposed
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to broad PDE4 inhibition could be a potential therapeutic target in the future not only for the
treatment of anxiety disorders, but perhaps negative emotional memory disorders as well.
It was noted that PDE4A KO did not alter the baseline of FST or TST behavior relative to
WT controls, in contrast to PDE4D KO, which produces antidepressant-like behavior (Zhang et
al. 2002). However, this does not mean PDE4A is not involved in antidepressant activity given
that its levels in the brain are highly responsive to antidepressant treatment (Ye et al. 2000;
D’sa et al. 2005). Further studies with chronic mild stress may help to clarify this.
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Chapter 3
PDE4A KO and Obesity
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3.1. Introduction
Obesity is a disorder that has risen to the ranks of national pandemic affecting ~30% of
the population, and costing the United States over 150 billion dollars a year (Ogden et al. 2012).
Obesity is also major risk factor for leading causes of death such as cardiovascular disease, stroke,
and diabetes. Obesity is defined as a body mass index of over 30 kg/m2, or a body fat percentage
over 25%. Sadly, obesity is one of the most preventable disorders in the country; however, due
to cultural changes such as increased work load, decreased time for exercise, and overabundance
of affordable easily obtainable trans-saturated fats, it has become a pandemic to which our
country is currently losing. These statements are made evident by the fact that zero states have
been able to reduce their obesity rating below 15% as set forth in the United States healthy
people 2010 pledge(Services 2010).
Obesity can be caused by many things in addition to lack of exercise and poor nutritional
intake such as drug side effects (SSRIs, antihypertensives, steroids), diseases (hypothyroidism,
Cushing’s syndrome, depression, anxiety), or genetics (heritability of obesity or high BMI has
been predicted to be as high as 84%) (O’Rahilly and Farooqi 2006). Because of this, there truly
is a need to develop new therapies since obesity is not always preventable, or able to be
attenuated by lifestyle changes. In addition, while much is known about the hormonal patterns
involved with obesity, there is still much to be characterized regarding CNS-mediated neural
correlates.
Obesity is a complex, multifactorial disease that can be influenced by a number of
different body systems and variables. When trying to identify the mechanisms by which a
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variable affects adiposity, one must take many things into consideration. This includes
hormonal control exerted by the central nervous system and peripheral organs, adipogenesis,
adipolysis, adipocyte size, exercise or baseline movement, food consumption, and metabolic
rate to name a few. For example, it is well known that leptin (a satiety signal secreted from
adipocytes) can decrease appetite and adipogenesis through inhibition of the neuropeptide Y
(NPY) and Agouti-related peptide (AgRP) which reside in AgRP/NPY neurons in the arcuate
nucleus of the hypothalamus. Leptin KO mice (ob/ob mice) become severely obese, mostly due
to uncontrolled eating resulting from a lack of satiety signal. Interestingly, in humans, obesity is
often associated with extremely high levels of leptin characteristic of “leptin resistance”
putatively due to a loss of sensitivity to leptin resulting in dysregulation of homeostaticfeedback mechanisms.
There are many treatments or ways to prevent obesity including routine exercise, living
an active lifestyle, and most importantly making healthy lifestyle choices such as eating
nutritionally well balanced meals, and avoiding trans-saturated fats. When obesity reaches
dangerous or life threatening levels, more extreme therapies are also available such as gastric
bypass surgery, which is effective but expensive, and can have severe consequences such as
hemorrhaging, bowel obstructions, infection, anastomotic leakage, dumping syndrome, ulcers,
hernias, nutritional deficiencies, and even death. Anti-obesity drugs such as orlistat (inhibits
pancreatic lipase), sibutramine (selective serotonin-norepinephrine reuptake inhibitor),
rimonabant (cannabinoid 1 receptor antagonist), metformin (AMP-activated protein kinase
activator), exenatide (GLP-1 analogue), and pramlintide (amylin analogue) are available however
they have severe drawbacks. Many of them have severe health concerns and have been pulled
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by the FDA (sibutramine, rimonabant), while other treatments are approved only for use in
diabetes related obesity (meformin, exenatide, and pramlintide).

Currently the only FDA

approved therapy for obesity is Orlistat, which is a pancreatic lipase inhibitor. The simple fact
that obesity prevalence is significantly increasing every year indicates a need for additional
therapies to help alleviate this disorder; phosphodiesterases may represent a novel therapeutic
target for combating obesity.

The role that cAMP and PDEs play in obesity is beginning to be uncovered; however much
more research is needed in order to characterize the complex regulation cAMP has on adiposity.
It is well known that PDE3B plays a very large role in insulin-mediated lipogenesis (Omar et al.
2011). This is largely due to the activation of PDE3B by insulin, which results in a subsequent
decrease of cAMP and lowered activation of hormone sensitive lipase, which ultimately
decreases lipolysis in adipocytes. However, it is unreasonable to assume an overall activation of
PDEs results in a lipogenic profile since PDEs have an extensive variation of expression and
functional roles in the body. Interestingly, inhibition of PDE1C, PDE3B, PDE4C, and PDE8B
resulted in increases of insulin secretion from rat pancreas (Waddleton et al. 2008). Also,
inhibition of PDEs results in a decrease of glucose uptake by adipocytes (Mors-Fletchtner et al.
2005). It is important to remember that chronically high levels of glucose in the blood stream
can lead to insulin resistance. Thus, lowered PDE activities in individuals, and subsequently
elevated cAMP levels, could possibly lead to insulin resistance due to chronically elevated insulin
release and high glucose levels. In agreement with this is the finding that PDE4 activity is
significantly reduced in obese mice (Greene et al. 2009). Furthermore, it has been shown that
PDE4 activity is significantly reduced in the adipocytes of obese individuals (Omar et al. 2011).
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Since it appears that PDE4 activity may be decreased in obese individuals, one would expect the
downstream effects of cAMP to be increased. Moreover, it has been shown that CREB activation
is significantly elevated in obese mice (Qi et al. 2009). CREB activation induces adipogenesis in
3T3-L1 cells (Reusch et al. 2000), and mice fed a high fat diet have elevated levels of pCREB and
BDNF in the striatum, which is correlated with a strong anxiogenic and depressive profile (Sharma
and Fulton 2012). The mechanism behind this rise in activated CREB may also be more than just
elevated cAMP signaling, as it has been shown that mice fed a high fat diet also have significantly
lower levels of the CREB inhibitor ICER. However, there are also paradoxical publications that
show PDE4 inhibition induces weight loss through increased lipolysis (Nakamura et al. 2004;
Snyder et al. 2005). The effect of PDE4 inhibitors to induce lipolysis may be mediated by PDE4B,
which has been shown to be expressed at levels more than twice as high compared to PDE4A in
adipocytes (Wang and Edens 2007). Supporting this is the evidence that PDE4B KO mice are
leaner than WT littermates, and protected against obesity (Zhang et al. 2009) This fact once again
details the incredible complexity and functional roles that different PDE4 subtypes might have,
and the lack of specificity able to be achieved by broad PDE4 inhibitors. This leads to the objective
of specific aim 2, to identify the role that PDE4A plays in obesity. Our hypothesis is that
decreasing PDE4A expression and activity will be lipogenic. The rationale behind our hypothesis
is that PDE4 activity is strongly reduced in obese individuals, and downstream molecules such as
pCREB and BDNF are elevated. In addition, it has also been shown that inhibition of adenylyl
cyclase V, which results in less cAMP, is protective against a high fat diet (Ho et al. 2011). One
additional piece of evidence is the fact that inhibition of PDE4A5 resulted in a significant
potentiation of growth hormone induced adipogenesis (MacKenzie et al. 1998) Interestingly, this
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study also showed that PDE4A5 is capable of being activated by p70S6 kinase. Leptin has also
been shown to activate P70 S6 kinase, indicating that PDE4A5 may be a downstream effector of
leptin mediated satiety and thermogenesis. In agreement with this is the fact that leptin has also
been shown to reduce cAMP in the NPY neurons of the arcuate nucleus, while ghrelin has the
opposite effect (Zhao 2005). While it is known this is mediated through PDE3B, the role of PDE4A
cannot be ruled out.

We performed several experiments in order to characterize the role PDE4A may play in
obesity. First, we used PDE4A KO mice to determine the effect of PDE4A depletion on baseline
weight gain. Second, we determined if PDE4A KO affects food consumption. Lastly, we examined
the effects of PDE4A KO on baseline metabolism by assessing the levels of T3 hormone present
in the blood of PDE4A KO mice vs WT controls.
3.2. Materials and Methods
Animals
All procedures were approved by the Animal Care and Use Committee of West Virginia
University Health Sciences Center and performed according to the recommendations of the NIH
Guide for the Care and Use of Laboratory Animals 7th edition (NIH Publications No. 80-23,
revised 1996). Adult male PDE4A KO mice on a C57 background were generated by
homologous recombination and heterozygote breeding as already described previously (Jin et
al. 1999; Jin and Conti 2002; Ariga et al. 2004; Jin et al. 2005a; Bruss et al. 2008; Jin et al. 2010).
In brief, the PDE4A gene was disrupted though replacement of a 3 kb region encoding exons 1014 using a PGK-hrpt cassette in the reversed orientation via homologous recombination. These
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PDE4A KO mice are commercially available through the Mutant Mouse Regional Resource
Centers which also provides additional details on their generation (MMRRC;
http://www.mmrrc.org; Stock number 034793-UCD). Age-matched (4-8 months) wild-type
(WT) mice (C57BL/6J) of the same background were used in this study. All genotyping was
confirmed by Southern blot analysis with tissues obtained via tail clipping and subsequent
detection of genomic DNA. Animals were housed in groups of 1-5 per cage (Allentown XJ cage,
12.5” length x 6” width x 5” height, 75 square inches of floor space) in a light (12 h on, 12 h off;
lights on at 0600 h) and temperature controlled room (22-23⁰C). Water and food were
available ad libitum
Locomotor activity
Mice were placed into individual PAS automated open field chambers (San Diego Instruments
San Diego, CA). The number of light beam crossings for locomotor activity (horizontal
crossings) and rears (vertical crossings) were recorded and averaged over six 5-min intervals
(Hu et al. 2011).
Food Consumption
To monitor the effect of PDE4A KO on food intake, the levels of food were monitored for 3
days. Mice were habituated to individual housing over the course of several days. After several
days, food intake was assessed by weighing the food each consecutive morning for 3 days.
T3 Levels
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To determine the effect of PDE4A KO on metabolism, the levels of T3 hormones were
measured. Blood was collected into a heparin tube by using a mouse 5.5mm goldenrod animal
lancet to puncture the submandibular vein. Blood plasma was then separated via
centrifugation and subsequent decanting of the plasma layer. Plasma T3 levels were obtained
via a T3 ELISA (CALBIOTECH, cat# T3043T-11).
Statistical Analysis
All data shown are means ± SEM, and were analyzed using the GraphPad Prism 5 software
(version 5.04). Locomotor activity was analyzed via 2-way ANOVA with repeated measures and
Bonferroni’s post test. Food consumption, weight, and T3 levels were analyzed via students
two-tailed T-tests. Alpha significance was achieved with a P value of < 0.05.
3.3. Results.
3.3.1. PDE4A KO and weight gain
To determine the effect of PDE4A KO on
weight gain, the body weights of PDE4A
KO mice and WT controls were measured
up until 8 months of age when the
behavior tests ceased. It was discovered that PDE4A KO mice had a significantly higher body
Figure 3.1. The effect of PDE4A KO on weight
gain. PDE4A KO mice weighed significantly
more than WT controls. The data displayed
represents the average weight of the mice from
3-8 months of age when the weight was
observed to plateau.

weight than WT controls (t= 5.010, P = .0002;
Figure 3.1) starting around 3 months of age.
This weight plateaued and remained the same
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until the animals were sacrificed around 8 months of age.
3.3.2. PDE4A KO and locomotor activity
To determine the effect of PDE4A KO on locomotor activity, animals were placed into a PASautomated open-field chamber and the number of light crossings recorded and averaged over
six 5-min intervals. PDE4A KO mice and WT controls displayed no significant difference in
locomotor activity, and light beam crossings for both groups decreased significantly over time
(2-ANOVA-R: significant effect of time, F(5,130) = 16.57, p < 0.0001; no effect of genotype, F(1, 26) =
2.19, p = 0.151; no effect of genotype x time interaction, F(5,130) = 0.75, p = 0.585; Figure 2.2a).
As an additional measure of exploratory activity, the number of rears was also recorded while
the mice were in the open-field chambers. It was found that PDE4A KO mice did display
significantly lower rearing levels than
WT controls during the first 15 min of
the test (2-ANOVA-R: significant effect
of PDE4A KO, F(1,26) = 12.77, p =
0.0014; significant effect of time x
genotype interaction, F(5,130) = 2.36, p =
0.0438; no effect of time, F(5,130) =
2.27, p = 0.052; Figure 2.2b). This data
indicates that while PDE4A KO did not

Figure 3.2. Effects of PDE4A KO on food consumption. PDE4A KO
mice displayed no changes in food consumption compared to WT
controls. Data shown represent means ± SEM; n = 9/group; (two-way
ANOVA with Bonferonni multiple comparison tests).

induce lethargy as interpreted by a lack of
changes in horizontal light crossings, there was a decrease in vertical exploratory rearing.

94

3.3.3. PDE4A KO and food consumption
To determine if the change in weight displayed with PDE4A KO was due to hyperphagia, food
intake was monitored in PDE4A KO and WT mice for 3 days. It was found that PDE4A KO mice
did not display elevated levels of food consumption when compared to WT controls, and
actually ate significantly less total food when normalized for body weight (2-ANOVA-R:
significant effect of PDE4A KO, F(1,14) = 6.42, p = 0.0238; no effect of time x genotype interaction,
F(2,28) = .56, p = 0.5765; significant effect of time, F(2,28) = 4.08, p = 0.0278; Figure 3.2).
3.3.4. PDE4A KO and T3 levels
To determine if the effects of PDE4A KO on
weight gain were due to changes in metabolism,
we investigated levels of the main metabolic
hormone T3 in PDE4A KOs vs WT controls. In
order to ensure that any change observed in
PDE4A KO animals was specific to PDE4A, we
also investigated the levels of T3 in PDE4B KO
mice and WT littermates. PDE4A KO animals
displayed significantly lower levels of T3
hormone than WT controls animals (t= 3.536, P

Figure 3.3. Effect of PDE4A KO on T3 levels. PDE4A KO mice
displayed significantly lower T3 levels than WT controls. In
addition, this decrease of T3 was specific to PDE4A KO as
PDE4B KO mice did not display decreased levels of T3
hormone. Data shown represent means ± SEM; n = 9/group;

= .0054 Figure 3.3). This suggests that PDE4A
KO may alter baseline metabolism, and this effect is specific to PDE4A and not PDE4B.
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3.4. Discussion.
In this study we have shown that PDE4A KO results in an obesogenic phenotype. PDE4A KO
mice were significantly heavier than WT controls, upwards of 45g compared to the average of
30g for WT mice. The next goal was to determine a possible explanation for this weight gain.
There are many possible avenues for obesity to occur such as: decreased activity, increased
food consumption, decreased metabolism, increased adipogenesis, increased absorption of fats
and nutrients, and increased baseline adipocyte size. To determine if changes in activity were
causing the obesity, PDE4A KO mice were subjected the open field locomotor test. It was
observed that PDE4A KO mice displayed no significant changes in activity over a 30 minute
period. This data suggests that changes in activity levels are not responsible for the observed
obesity in PDE4A KO mice. Additional home cage baseline activity tests in the future however
should be used to confirm these findings (i.e. use of a home cage monitoring system). The next
possible cause for obesity that we tested was food consumption. It has been shown that mice
with alterations in leptin signaling (one of the main satiety hormones) become severely obese
due to hyperphagia and hypometabolism. Essentially these ob/ob mice have no satiety signals
and excessively consume food until they become morbidly obese. To test for hyperphagia, we
acclimated the animals to single housing. After single housing, the amount of mouse chow in
the cages was weighed every day to determine the amount of food being ate. Surprisingly,
PDE4A KO mice showed no significant changes in food consumption compared to WT controls
over the course of 3 days, suggesting that food consumption was not one of the major
mechanisms responsible for the obesogenic profile in these animals.
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Next, we decided to examine the effects of PDE4A KO on triiodothyronine hormone (T3),
one of the major metabolic hormones of the body. T3 exerts these effects through a number of
mechanisms such as glycogen breakdown and lipolysis. In order to show that any possible
effects of PDE4A KO on T3 were specific, we also decided to look at PDE4B KO mice T3 levels.
T3 ELISA absorptions determined that PDE4A KO mice had significantly lower T3 levels than WT
controls. In addition, this effect was specific to PDE4A KO mice, as PDE4B KO mice did not
display any change in T3 levels. These findings suggest that PDE4A KO therefore may induce
obesity through changes in the metabolic hormone T3, and the subsequent basal metabolic
rate of the body. This is not believed to be a compensatory change, as in the clinic obese
individuals typically have elevated T3 levels, which is perhaps a response of the body to try to
decrease their weight (Faber et al. 1981). The T3 levels also shed light onto a possible
relationship between the anxiogenic phenotype observed in PDE4A KO mice (see chapter 2). As
mentioned, it has been shown that anxiety, depression, and obesity are highly co-morbid in the
human population (Simon et al. 2007), a result that was also observed in the PDE4A KO mice
phenotype. The relationship between stress, anxiety, and T3 levels is a complicated one, and
additional research is needed (Faber et al. 1981; Williamson and Davison 1987; Munjack and
Palmer 1988; Byerly et al. 2009). However, it has been shown that stress and anxiety in rats can
result in hypothyroidism (Olivares et al. 2012) and lowered T3 levels (Helmreich et al. 2005;
Helmreich and Tylee 2011). Thus, it seems rationale to assume that the strong anxiogenic
phenotype observed in PDE4A KO mice could have attenuated the release of T3, and resulted in
the subsequently observed obesity. Interestingly, it has also been shown that mice with
decreased thyroid signaling display anxiogenic behavior, and that supplementation with T3
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reversed this phenotype (Venero et al. 2005; Buras et al. 2014). Thus it appears that the
influence of anxiety on T3, and conversely T3 on anxiety, could be cyclical, with a positive
feedback loop occurring in the PDE4A KO mice.
While we believe that changes in baseline metabolism due to changes in T3 levels may be a
primary cause for the obesity in PDE4A KO mice, there are other mechanisms we have not
tested that could also be playing a role. One additional explanation for the obesity observed in
PDE4A KO mice could be due to increased adipogenesis. While there is very little research on
the regulation of PDE4, cAMP, and obesity, there is one study which shows that in
preadipocyte-3T3-F442A fibroblast cells, antisense deletion of PDE4A5 resulted in a higher
differentiation rate of fibroblasts into adipocytes. Conversely, it was shown that growth
hormone induced activation of PDE4A5 served as a “brake” for the differentiation process;
particularly, PDE4A5 was specifically activated by P70S6 Kinase (MacKenzie et al. 1998). Thus in
this “model of adipogenesis”, it appears that depletion of PDE4A5 leads to increased
“adipogenesis”, and activation of PDE4A5 led to lowered adipogenesis rates. This in vitro data,
while not causal, is consistent with what we observed in PDE4A KO mice. If depletion of
PDE4A5 does cause increased adipogenesis, then this is one mechanism through which the
PDE4A KO obese phenotype could be explained. Leptin has also been shown to activate P70S6
kinase, indicating that PDE4A5 may be a downstream effector of leptin mediated satiety and
thermogenesis. In agreement with this is the fact that leptin has also been shown to reduce
cAMP in the NPY neurons of the arcuate nucleus, while ghrelin has the opposite effect (Zhao
2005). While it is known that this is mediated through PDE3B, a role for PDE4A cannot be ruled
out.
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Additional studies have also provided evidence that increased cAMP signaling
(decreased PDE4 activity) may be a possible mechanism of obesity. It has been shown that
PDE4 activity is significantly reduced in both obese mice (Greene et al. 2009) and adipocytes
from obese humans (Omar et al. 2011). Since it appears that PDE4 activity may be decreased in
obese individuals, one would expect the downstream effects of cAMP to be increased.
Moreover, it has been shown that CREB activation is significantly elevated in obese mice (Qi et
al. 2009). CREB activation induces adipogenesis in 3T3-L1 cells (Reusch et al. 2000), and mice
fed a high fat diet have elevated levels of pCREB and BDNF in the striatum, which is correlated
with a strong anxiogenic and depressive profile (Sharma and Fulton 2012). The mechanism
behind this rise in activated CREB may also be more than just elevated cAMP signaling, as it has
been shown that mice fed a high fat diet also have significantly lower levels of the CREB
inhibitor ICER. It has also been shown that inhibition of adenylyl cyclase V, which results in less
cAMP, is protective against a high fat diet (Ho et al. 2011).
While there have been many studies suggesting that increased cAMP is obesogenic,
there have also been many studies showing that PDE4 inhibition actually protects against high
fat diets (Nakamura et al. 2004; Snyder et al. 2005; Park et al. 2012; Doseyici et al. 2014). However, it
is important to remember the incredible complexity and compartmentalization of cAMP and
PDE signaling (Houslay et al. 2007; Lynch et al. 2007; Baillie 2009; Houslay 2010). While PDE4A
KO mice in our study were obese, it was previously shown in other labs that PDE4B KO may be
protective against obesity (Zhang et al. 2009). It is not surprising that broad PDE4 inhibition
with a drug throughout the entire body would have significantly different effects than local
inhibition of a single splice variant in one region of the body.
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An additional mechanism for which we were unable to test for was altered absorption
of fat and nutrients in PDE4A KO mice. This could be broken down into initial absorption of fats
and nutrients in the GI tract, as well as cellular uptake of glucose and fat. In regards to the
absorption of nutrients in the GI tract, the microbial flora found in the small intestine and colon
play a significant role in this absorption. Mediation of inflammatory factors and the immune
response could have significant impacts on the characteristic of these microbial flora. It has
been shown that PDE4B regulates the release of certain inflammatory factors, thus it is a
possibility that PDE4A could also be playing such a role. However this possibility is more
unlikely as PDE4B was suggested as the primary PDE4 subtype responsible for the mediation of
this response (Jin and Conti 2002).
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Chapter 4
Conclusions and Future
Studies/Directions
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4.1 Conclusions
The goal of this dissertation was to characterize the functional role that PDE4A plays in both
behavior and obesity. In summary, this dissertation has shown that PDE4AKO:
 Displays no effect on locomotor activity, but significantly reduced rearing levels

 Induces anxiety-like behavior as measured by the elevated plus maze, hole board , lightdark transition, and novelty-suppressed feeding tests
o This change in anxiety-like behavior also correlated with prolonged and elevated
levels of corticosterone in PDE4A KO mice in response to food-deprivation stress

 Displays no change in depressive-like behavior as measured by the forced-swim and tailsuspension tests

 Improves “emotional memory” as measured through step-through passive avoidance

 Has no effect on “episodic-like” memory in the novel object recognition test

 Impairs spatial memory training in the Morris water maze, however retrieval appeared
unaffected

 Increases cAMP and pCREB levels in the hippocampus and frontal cortex

 PDE4A KO is obesogenic
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o This gain in weight was not due to differences in activity or food consumption,
and was most likely metabolic as T3 hormone levels were significantly reduced in
PDE4A KO mice
These studies have significantly improved our knowledge of the PDE4A subtype and its
functional role in the body. However, further studies are needed to characterize the
mechanisms by which PDE4A modulates anxiety, emotional memory, and obesity.
4.2. Future Studies and directions
While this dissertation has begun to characterize the functional role that PDE4A plays in
behavior and obesity, we have yet to identify the exact mechanisms by which it does so. The
following studies would significantly further our knowledge of the mechanisms behind PDE4A
KO and anxiety/obesity.
4.2.1. Investigating the effects of stress and anxiety on PDE4A expression and activity. In this
dissertation we have shown that PDE4A KO mice display a strong anxiogenic phenotype. Due to
the fact that loss of PDE4A expression promotes anxiety-like behavior, it is reasonable to
suggest that inducing stress and anxiety in WT mice would alter PDE4A expression and activity
in anxiety-related regions of the body. Our hypothesis is that PDE4A expression and activity
would be decreased after stress in anxiety related brain regions such as the prefrontal cortex,
amygdala, and hippocampus. The rationale behind our hypothesis is that depletion of PDE4A
induces anxiety, so it is logical to assume that PDE4A expression and activity would have an
inverse relationship. This is supported by evidence that elevation of cAMP in the amygdala
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correlates with anxiety. We propose that WT C57 mice should be restraint stressed for various
periods of time (1-10) days. The effects of stress and anxiety on PDE4A expression/activity
would be looked at during following time points after the stress (immediately after, hours after,
day after, etc.) This paradigm would allow the researcher to determine the immediate effects
of stress on PDE4A expression and activity, as well as long term changes. Sampling the effects
of stress on PDE4A function at multiple time points also offers a better insight into the time
course of any changes observed. PDEs are notorious for being incredibly compensatory, so it’s
possible that PDE4A levels could have opposite expression patterns in acute vs chronic stress.
Sampling at multiple time points would allow all these patterns to be observed. Supporting this
theory, it has been shown that after unpredictable foot shock stress, PDE4A1, PDE4A5, and
PDE4A10 mRNA transcripts are decreased in the basolateral nucleus of the amygdala (Stair and
Rainnie 2011). While this study is an important first step in agreeing with our theory that
increased cAMP signaling in the amygdala correlates with anxiety, these findings need
confirmed with western blot and protein levels. In addition, this study has not ruled out
whether the decreased expression of PDE4A mRNA transcripts is compensatory, or whether
these decreased levels are directly causing the anxiety-like behavior observed. Additional
studies explained below could help to answer these questions.
4.2.2. Can the PDE4A KO phenotype be rescued by overexpression of PDE4A? While the PDE4A
KO mice we studied displayed significant changes in obesity and anxiety, global KO mice have
their limitations. First, we are unable to rule out the effects of development on behavior. It is
possible that PDE4A KO changed the formation and connections of the brain which could
inherently result in changes in behavior and obesity. In addition, we are not able to rule out
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indirect changes of PDE4A KO on behavior and obesity. Rescue studies are strongly suggested
when further trying to validate the results seen in a knock out study. In order to perform this
experiment, PDE4A would need to be overexpressed in the brains of PDE4A KO mice. This
could be done through lentiviral vectors infused into various parts of the brain we believe could
be responsible for the manifestation of anxiety, emotional memory, and obesity such as the
prefrontal cortex, amygdala, hippocampus, and hypothalamus. If the phenotype of PDE4A KO
mice were able to be reversed through the overexpression of PDE4A, it would further validate
our hypothesis on the specific role of PDE4A in these conditions.
4.2.2. Does PDE4A inhibition and overexpression in WT mice modulate anxiety-like behavior and
obesity? While there are currently no specific PDE4A activators or inhibitors available,
overexpression and inhibition of the PDE4A enzyme could be performed through viral vectors
carrying dominant negatives and overexpression constructs. These viral vectors are currently
available and ready for use. Specifically increasing PDE4A levels, or inhibiting the PDE4A
enzyme would answer many questions. First, by inhibiting the enzyme or increasing its
presence in adult mice, the confounding effects of development can be ruled out. In addition,
this study would also be able to rule out the possible confounding variable of peripheral effects.
PDE4A is not expressed uniquely in the brain, it is also in other areas of the body such as the
adrenal cortex, thyroid gland, pancreas, and adipocytes which could cause changes in these
areas indirectly causing the anxiety-like behavior and obesity observed in the PDE4A KO mice.
For example, while we hypothesized that the amygdala is being over activated by elevated
cAMP levels due to loss of PDE4A, it is possible that the adrenal cortex is being changed by loss
of PDE4A, and subsequent cAMP signaling as well (Bourdeau and Stratakis 2002). If PDE4A KO
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were to cause more corticosterone to be released from the adrenal cortex, this could possibly
be responsible for the change in behavior we observed. This would be a very powerful study
because it would specifically show the causal relationship between PDE4A and the results we
observed in PDE4A KO mice. Also, this study would be able to narrow down which PDE4A splice
variants are relevant for anxiety, as well as which brain regions are playing a role.
4.2.4. The effect of HCN channels on PDE4A and anxiety. As mentioned earlier, HCN channels in
the mPFC could be playing a significant role in the manifestation of anxiety-like behavior
observed in PDE4A KO mice. To further characterize the cAMP pathway involved with this
behavior, HCN channel inhibitors could be infused into the mPFC of PDE4A KO mice. We
hypothesize that inhibition of HCN channels in PDE4A KO mice would attenuate the anxiety-like
behavior observed and partially rescue the PDE4A KO anxiogenic phenotype.
4.2.5. Further characterizing the causal relationship between PDE4A KO and obesity. We
observed in these studies that PDE4A mice display both significant anxiety-like behavior, and
obesity. These findings are consistent with the high comorbidity of anxiety and obesity
observed in the human population. While we were able to document and record these
findings, we are still uncertain of the causal relationship between the two. It is very possible
that increased anxiety-like behavior is stressing the body, causing inflammation and subsequent
alterations in adipocyte characteristics as well as changes in the base-line metabolism we
observed as a decrease of T3 hormone. In addition, it is also possible that the obesity appeared
first and that this stress on the body caused increased anxiety-like behavior both through direct
and indirect mechanisms. Further characterization of this relationship would significantly help
to identify the mechanisms with which PDE4A modulates these conditions. One experiment
106

could be to give anxiolytics such as BZDs or SSRIs to PDE4A KO mice at a young age to see if
they could prevent the significant weight gain observed. An alternate approach could be to
more closely monitor PDE4A KO mice for behavior at a younger age to try to illicit which
characteristic appears first. To determine if the obesity is affecting the anxiety, PDE4A KO mice
could have their diet supplemented with replacement T3 hormone. After a period of time, the
change in anxiety-like behavior and obesity levels could be measured. These studies are further
supported by literature showing that stress and anxiety can decrease thyroid function
(Helmreich et al. 2005; Helmreich and Tylee 2011; Olivares et al. 2012), and that decreased
thyroid function can also cause stress and anxiety (Venero et al. 2005; Buras et al. 2014).
4.3. Summary
With these initial studies, and further characterization of the mechanisms by which
PDE4A modulates anxiety-like behavior and obesity, we believe that PDE4A could someday be a
potential target for anxiety, emotional memory disorders, and obesity. PDE4A KO had no effect
on locomotor activity, therefore we believe that targeting PDE4A as an anxiolytic could avoid
the side effects of sedation and lethargy which plagues BZDs. In addition, we believe that it is
important to recognize the incredible complexity of cAMP/PDE signaling and that inhibition of
PDEs may not be the appropriate therapy in all scenarios. With the previous sections in mind,
one can recognize the incredibly delicate balance of cAMP signaling that occurs in the brain,
and that global activation of cAMP through broad PDE4 inhibition might not be the best
approach. As mentioned, in regards to WM it appears that decreases in cAMP levels in the PFC
would actually improve memory. This also might hold true in the nucleus accumbens and
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amygdala, as overexpression of CREB in these region has been shown to produce anhedonia
(Muschamp et al. 2011) and anxiety (Wallace et al. 2004), respectively.
There appears to have been a “herd mentality” in the field of PDE4 research, as PDE4
inhibition is consistently talked about as if it is the only mechanism through which PDE4
modulation could have beneficial effects. However, this is starting to appear too simplistic, and
there may need to be a paradigm shift in the way we think about PDE4 modulation as a
therapeutic for cognitive disorders; in particular, researchers may need to begin thinking about
PDE4 activation as a possible therapeutic strategy for the future. This makes particular sense in
regards to anxiety or working memory. However, it appears in regards to hippocampusdependent memory that PDE4 inhibition may still be the best approach.
4.4. Contributions.
Portions of this section were taken from a soon to be published review “Phosphodiesterase-4
modulation as a potential therapeutic for cognitive loss in pathological and non-pathological
aging: Possibilities and Pitfalls”.
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